NZ612615B2 - Use of toll-like receptor agonist for treating cancer - Google Patents

Abstract

Disclosed is the use of a Toll-Like Receptor (TLR) agonist for the manufacture of a medicament for the treatment of cancer in a mammal, wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8, wherein the sequence is as defined in the specification. d in the specification.

Description

USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER FIELD OF THE INVENTION This invention relates to methods of treating cancer in Toll—Like Receptor—expressing tissues, and to methods of protecting the liver from the effects of a liver toxicity, using a TLR agonist.

BACKGROUND OF THE INVENTION Interaction between members of the death receptor family and their cognate ligands s apoptosis controlling the homeostasis of cell populations in tissues, particularly in the immune system. Although many tumor cell types are sensitive to death ligands, activation of Fas signaling also induces massive apoptosis in the liver leading to organ e and death precluding its use for systemic anticancer therapy. Fas ligand is a 40 kDa physiological agonist of Fas signaling expressed on activated lymphocytes and many tumor cells which can also be secreted through metalloproteinase—mediated cleavage and kill the sensitive cells in autocrine and paracrine manner. Fas is a transmembrane receptor expressed on activated lymphocytes, variety of tissues and tumor cells. Fas signaling plays crucial role in regulation of the immune system by triggering autocrine suicide or paracrine death (apoptosis), suppressing immune reaction by eliminating activated lymphocytes. Upon g, it induces p53 ndent cell death h extrinsic pathway of apoptosis engaging DISC ion, caspase—8 and 10, and intrinsic (mitochondrial) apoptosis activating caspase—8 and Bid cleavage, and rome release. Both apoptotic pathways lead to activation of caspase—3 and 7. Mitochondrial apoptosis is ted by pro— and anti—apoptotic Bc12 family s. In tumor cells, Fas ing is often found deregulated either by absence of Fas receptor, or by constitutive activation of NF—kB resulting in the expression of anti—apoptotic genes, such as c—Flip, Bcl—2, Bcl—xL. C—Flip, an NF— kB responsive gene, has been trated to inhibit e—8 and Fas mediated apoptosis in tumors (REFs, Kataoka et a12000).

Upon discovery of p53 independent apoptotic mechanism h Fas, TRAIL and TNFOL death receptor signaling, they seemed to be promising targets for anti—cancer therapy since tumor cells usually have impaired p53 function. A severe hepatotoxicity, however, is induced by death receptor ligands. This has hampered development of these anti—cancer therapies. While Fas ts cause liver damage and TNF—a induces strong inflammation in liver, lungs and other organs, TRAIL is the least toxic in humans. TRAIL has therefore received more attention than other agonists for the al application for an anticancer treatment. Many tumors, however, are not sensitive to TRAIL therapy. Several ches to e death receptor ty issue are currently undertaken, most of which are aimed to increase tumor sensitivity by blockage of NF— kB activity and increasing receptor expression thus reducing the amount of drug necessary for the effective therapy. Another direction is to ze the drug delivery to the tumors to minimize toxic effects on distant organs. To date, there is no reliable approach to the tion of toxicity (including liver ) that would allow the systemic application of death receptor agonists in clinical trials. Accordingly, there is a need in the art for methods of preventing the undesirable effects of death receptors when they are used to treat cancer. In particular, there is a need to protect the liver from these undesirable effects. There is also a need for protecting the liver from liver toxicities in general.

TLRs are found to be expressed on both epithelial and endothelial cells as well as immunocytes. At present, thirteen TLRs have been identified in mammals. Upon receptor stimulation, several common signaling pathways get activated such as NF—kB, AP—l, PI3K/AKT and mitogen—activated protein kinases (MAPK) leading to increased survival, stimulation of cell proliferation and the secretion of many cytokines with chemotactic and pro—inflammatory functions. Induction of TLR in cancer cells can be used to treat cancer, however, the distribution of different TLRs varies significantly among the various organs and cell types. This affects the cytokine e and extent of the inflammatory se of cells. Accordingly, there is a need in the art for cancer immunotherapeutic methods that do not depend on the presence of TLR5 expression.

SUMMARY OF THE INVENTION Provided herein is a method of treating cancer in a mammal, which may se administering to a mammal in need thereof of Toll—Like Receptor (TLR) agonist. Also provided is a method of reducing cancer recurrence in a mammal, which may comprise administering to a mammal in need thereof a TLR agonist. The cancer may be t in a tissue that expresses TLR. The cancer may be a metastasis or tumor regrowth. [0005a] In a first aspect there is ed Use of a Toll-Like Receptor (TLR) agonist for the manufacture of a ment for the treatment of cancer in a mammal, wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising an amino acid sequence of at least 95% identity with SEQ ID NO: 8.

] In a second aspect there is provided use of a Toll-Like Receptor (TLR) agonist for the manufacture of a medicament for the treatment of cancer in a , wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8. [0005c] It is to be noted that, throughout the description and claims of this specification, the word 'comprise' and ions of the word, such as 'comprising' and 'comprises', is not intended to exclude other variants or additional components, integers or steps. cations and improvements to the invention will be readily apparent to those skilled in the art. Such modifications and improvements are intended to be within the scope of this invention. [0005d] Any reference to or discussion of any document, act or item of knowledge in this ication is included solely for the purpose of providing a context for the present invention.

It is not suggested or represented that any of these matters or any combination thereof formed at the priority date part of the common general knowledge, or was known to be relevant to an attempt to solve any problem with which this ication is concerned.

The TLR agonist may be flagellin. The cancer may not express TLR, which may be TLRS. The tissue may be liver, lung, bladder, or intestinal. The cancer may be metastatic. The cancer may be melanoma, colon, breast, prostate, or a logical malignancy, which may be lymphoma. The cancer may be tumor.

The agent may be administered as a monotherapy. The mammal may not be receiving a combination y. The mammal may also not be receiving chemotherapy or radiation therapy, but may be treated surgically. The mammal may have sufficient innate immunity, which may be at a level that is equivalent to the level required for ility for a first or subsequent round of herapy. The mammal may have a white blood cell count within the range of normal, or may have a white blood cell count indicative of mild—immunosuppression. The TLR agonist may be administered to the mammal before, after or rent with removal of a tumor. The TLR agonist may be administered during tumor removal. r provided herein is a method of treating cancer in a mammal, which may comprise administering to a mammal in need thereof a FAS agonist and a TLR agonist, which may be flagellin. The FAS agonist may be a FAS agonist antibody. The cancer may be metastatic, and may be a tumor. The cancer may not express a TLR. The cancer may have metastasized to an invaded tissue that expresses TLR. The invaded tissue may be liver, bladder, lung, or intestinal.

Also provided herein is a method of protecting liver tissue in a mammal from the effects of a liver toxicity, which may comprise administering to a mammal in need thereof a TLR t. The toxicity may be a FAS ligand, a FAS agonistic antibody, TNFOL, acetaminophen, alcohol, a viral infection of the liver, or a chemotherapeutic agent. The toxicity may also be a Salmonella infection, which may be from Salmonella typhimurium. The TLR agonist may be BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the domain structure of bacterial flagellin. The Ca backbone trace, hydrophobic core distribution and structural information of F41. Four distinct hydrophobic cores that define domains Dl, D2a, D2b and D3. All the hydrophobic side—chain atoms are displayed with the Ca backbone. Side—chain atoms are color coded: Ala, yellow; Leu, lle or Val, orange; Phe and Tyr, purple (carbon atoms) and red (oxygen . c, on and region of various structural features in the amino—acid sequence of flagellin. Shown are, from top to bottom: the F41 fragment in blue; three b—folium folds in brown; the secondary structure distribution with a— heliX in yellow, b—structure in green, and b—turn in ; tic mark at every 50th residue in blue; domains D0, D1, D2 and D3; the aXial subunit contact region within the proto—element in cyan; the well—conserved amino—acid sequence in red and variable region in violet; point mutations in F4l that produce the elements of different supercoils. Letters at the bottom indicate the morphology of mutant elements: L (DlO7E, Rl24A, Rl24S, G426A), L—type straight; R (A449V), R-type straight; C (D3l3Y, A4l4V, A427V, N433D), curly33.

Figure 2 shows a schematic of Salmonella flagellin domains, its fragments, and its interaction with TLRS. Dark bars denote regions of the flagellin gene used to construct fragments comprising A, B, C, A’ and B’.

Figure 3 depicts flagellin tives. The domain structure and imate ries (amino acid coordinates) of selected flagellin derivatives (listed on the . FliC flagellin of Salmonella dublin is encoded within 505 amino acids (aa).

Figure 4 shows the nucleotide and amino acid sequence for the following flagellin variants: AA’ (SEQ ID NO: 7-8), AB’ (SEQ ID NO: 9-10), BA’ (SEQ ID NO: 11-12), BB’ (SEQ ID NO: 13-14), CA’ (SEQ ID NO: , CB’ (SEQ ID NO: 17—18), A (SEQ ID NO: 19— ), B (SEQ ID NO: 21-22), C (SEQ ID NO: 23-24), GST-A’ (SEQ ID NO: 25—26), GST—B’ (SEQ ID NO: 27-28), AA’nl-l70 (SEQ ID NO: 29-30), AA’nl—l63 (SEQ ID NO: 33—34), -l70 (SEQ ID NO: , AA’n54-l63 (SEQ ID NO: ), AB’nl-l70 (SEQ ID NO: 37—38), l63 (SEQ ID NO: , AA’nl-l29 (SEQ ID NO: 41-42), AA’n54-l29 (SEQ ID NO: 43-44), AB’nl-l29 (SEQ ID NO: 45-46), AB’n54-l29 (SEQ ID NO: 47-48), 100 (SEQ ID NO: 49-50), AB’nl-100 (SEQ ID NO: 51—52), AA’nl—70 (SEQ ID NO: 53— 54) and AB’nl—70 (SEQ ID NO: 55—56). The pRSETb leader sequence is shown in Italic (leader includes Met, which is also amino acid 1 of FliC). The N al constant domain is underlined.

The amino acid linker sequence is in Bold. The C terminal constant domain is underlined. GST, if present, is highlighted.

Figure 5 shows a comparison of amino acid sequences of the conserved amino (Fig. 5A) and carboxy (Fig. 5B) terminus from 21 species of bacteria. The 13 conserved amino acids important for TLRS activity are shown with shading. The amino acid sequences are identified by their accession numbers from TrEMBL (first letter 2 Q) or Swiss—Prot (first letter 2 P).

Figure 6 shows the sequence of human TLRS.

Figure 7 NF—kB activation in vivo in se to CBLB502 and LPS injections. A.

Background and NF—kB dependent luciferase expression in BALB/c—Tg(IKBOt—luc)Xen reporter mice was detected by noninvasive imaging 2 hs after the treatment with CBLB502 (0.2 mg/kg).

B. NF—kB dependent luciferase expression in liver, small intestine (ileum part), colon, spleen, kidneys, lungs and heart was assessed in the reporter mice 2 hs after s.c. injections of 100 ul of either PBS, CBLB502 (0.2 mg/kg) or LPS (1 mg/kg). Luciferase activity normalized per ug of the protein t was detected in 3 mice in each group. Bars represent e +/— s.d. C. The dynamics of NF—kB nuclear translocation (p65) indicative of the bioactivity of agonists LPS and CBLB502 in liver from NIH—Swiss mice injected s.c either with CBLB502 or LPS. Control mice were injected with PBS. Tissue samples were obtained 20, 40 and 60 min after the treatments, processed into paraffin blocks. Nuclear translocation of p65 in primary mouse hepatocytes isolated from NIH—Swiss mice (D) and human hepatocytes purchased from (BD Biosciences) (E) was detected after in vitro treatment with CBLB502 (100 ng/ml) or LPS (1 ug/ml) for indicated period of time. Control cytes remained intact. P65 was stained with green fluorescence, cytokeratin—8 with red fluorescence and nuclei with non—specific Dapi blue ng. Pictures are taken at x20 ication. Arrows indicate Kupffer and endothelial cells ined based on morphological criteria.

Figure 8 shows 2 protection from Fas mediated hepatotoxicity. A. Survival of NIH—Swiss mice after i.p. injection of 4 ug of as antibodies alone or in combination with CBLB502 (1 ug/ mouse) injected 30 min, 2 hours and 6 hours prior antibodies. In parenthesis are the numbers of mice per each treatment. B. tion of livers from anti—Fas antibody toxicity.

Apoptosis in livers 5 hours after injections of anti—Fas dies was detected using TUNEL que. C. Tissue morphology with H&E staining revealed necrotic damge to livers by anti— Fas antibody injections and protection by 2. D. Hemorrhage in liver was detected using erythrocyte autofluorescence (rhodamine channel, red), mouse IgG control (Cy5—conjugated anti— mouse IgG dy, pceudocolored in purple) and DAPI nuclei (blue). E. Caspase—3/7 activity in liver samples of NIH—Swiss mice was determined in tissue protein lysates 5 hours after injection of 3 ug anti—Fas antibody with or without CBLB502 thirty minute pre—treatment. N=3.

Bars represent average +/— s.d. F. Alanine aminotransferase (ALT) accumulation in blood serum of NIH—Swiss mice was detected 5 hours after as antibody ions with or without CBLB502. N=3. Bars represent average +/— s.d. G. Caspase—8 activity in liver samples of NIH— Swiss mice was ined in tissue protein lysates 5 hours after injection of 3 ug as antibody with or without CBLB502 thirty minute pre—treatment. N23. Bars represent average +/— s.d. .

Figure 9 shows regulation of apoptosis—related factors by CBLB502 in liver and its effect on diated antitumor activity in CT—26 tumor model. Inhibition of caspase—8 (A) and Bid (B) cleavage by CBLB502 detected in liver isolated from C57BL/6 mice 2 hours after anti—Fas dy injections (5 ug) alone or in ation with CBLB502 by western blot. C. RNA expression of Bcl2AlB, Bcl2AlD, IER—3, Fos, Jun and JunB genes in livers of intact mice and treated with 2 for 30 min and 2 hours was detected by . GAPDH was used as a control to monitor the induction of gene expression. D. Mice with s.c. growing CT—26 tumors were injected either with single anti—Fas antibodies (4 ug/mouse) and CLB502 or their combination. Control mice (“intact”) received PBS in replace of CBLB502 and antibodies. In hesis are the numbers of tumors in each group. The results represent the average tumor volumes (m +/— standard error). (*) — The difference between intact and combination treatment groups is significant (p<0.05). E. Mice were treated with anti—Fas antibodies alone or in combination with 2 on day 5 after plenic injection of luciferase expressing CT—26 tumor cells. Tumor growth in livers was determined using Xenogen IVIS Imaging System on the days 10, 15, 17, 22, 28 and 40 after tumor cell inoculation. Images of 3 mice from each group taken on day 15 are presented. The difference between proportions of mice with tumor—free livers in CBLB502—treated and control groups reaches statistical significance (p<0.05) on days indicated by asterisks. F. Migration and infiltration of immunocytes (arrows) into tumor nodules grown in liver of mice 5 hrs post treatment with CBLB502.

Figure 10. Dynamics of NF—kB activation in different organs after injections with CBLB502 (5 ug, s.c.) or LPS (20 ug, s.c.). Mice were euthanized 2, 6, 24 and 48 hours later by C02 inhalation. Luciferase activity in protein extracts from liver, large intestine, kidneys and lungs was normalized per ug of the protein extract and average values were calculated per organ.

Luciferase fold induction was calculated as ratio between average luciferase activity in protein t from organs of the TLR agonist treated mice and that obtained in the extracts from the corresponding organs of the PBS injected control mice (3 mice/ group). Bars represent fold induction as average i s.e.

Figure 11. NF—kB dependent luciferase expression in primary culture of mouse hepatocytes isolated from luciferase reporter mice and treated in vitro for 3 hours with CBLB502 (100 ng/ml), LPS (5 ug/ml) or PBS control. Then hepatocytes were rinsed with PBS and collected in cell lysis buffer ga). Luciferase activity in the protein supernatants was determined by Promega reporter system and normalized per ug of the protein extract. Bars represent luciferase units (mean i s.d.).

Figure 12. H&E staining of liver samples from NIH—Swiss mice treated with CBLB502, anti—Fas antibodies (3 ug) or their combination obtained at different time—points after the treatment. s of livers were obtained 5, 12 and 26 hours after injections of anti—Fas antibodies, fixed in 10% formalin, embedded in paraffin and stained for tissue morphology with hematoxilin and eo sin.

Figure 13. TLRS expression on B16 and CT—26 cells. A. sion of mRNA encoding TLR5 and GAPDH (as a control) genes in B16 and CT—26 cells were determined by RT—PCR. A region of mouse TLRS mRNA was ied using primers specific for the mouse TLRS gene: forward (5’-AGTCCCCCAGCTCCAGTTTC—3’) and reverse (5’—GGAGCCCCCTAGCAGTG AGT—3’). B. NF—kB activation in B16 and CT—26 tumor cells in response to CBLB502, mouse TNFOL and LPS was tested using luciferase er assay. Data represent rase units (mean i s.d).

Figure 14. Shows TLRS expresion in CT—26 tumor cells and A20 lymphoma cells. For Figs. 14A and C, total RNA was extracted from CT—26 and B16 tumor cells (Fig. 14A) and CT— 26 and A20 cells (Fig. 14C) using TRIzol reagent as bed in the main text of the manuscript. The primers for TLRS were designed using LaserGene software (DNASTAR, Inc., Madison, W1). A region of mouse TLRS mRNA (GenBank Accession No. NM_016928.2) was amplified using primers specific for the mouse TLRS gene: forward (5’— CCAGCTCCAGTTTC—3’) and reverse (5’—GGAGCCCCCTAGCAGTGAGT—3’).

GAPDH was used as a control to monitor the induction of gene expression. cDNAs were synthesized using SuperscriptTM II e Transcriptase and oligo(dT)12—18 primer (Invitrogen, Carlsbad, CA). B. An in vitro luciferase assay for NF—kB activation in B16 (TLRS positive) and CT—26 TLRS negative) tumor cells was performed.

Figure 15 shows the cs of TLR5 positive HCT116 tumor growth in athymic nude mice after CBLB502 or PBS (no treatment) treatments (0.2 mg/kg, s.c., days 1, 2, 3), n=6—10.

Figure 16 shows 293—TLR5 tumor growth in athymic nude mice after CBLB502 or PBS (no treatment) treatments (0.2 mg/kg, s.c., days 1, 2, 3), n=6—10.

Figure 17 shows the dynamics of xenogenic A549 tumor growth in athymic nude mice during 2 courses of CBLB502 vs. PBS (control) treatments (days 1, 2, 3, 14, 15 and 16), n=6—10.

Antitumor activity of colon HCT116 adenocarcinoma s.c. Grown as a xenograft in athymic mice.

HCT116 were ed s.c. into 2 flanks of 8 athymic nude mice (0.5x106 /100 n11 of PBS) to induce tumors. When tumors became of about 3—5 mm in diameter (by day 6 after injections) mice were randomly distributed into 2 groups, 5 mice for CBLB502 treated group and 3 mice in PBS control group.

Figure 18 shows the rate of SCCVII orthotopic tumor growth in syngenic C3H mice after CBLB502 or PBS (no treatment) ents (0.1 mg/kg, s.c.days l, 2, 3) to reach 400 mm3 tumor size, n=6—10. Right figure represents the amount of days needed for tumors to reach 400 m3 volume with and without treatment with CBLB502.

Figure 19. Fischer rats with s.c. growing syngeneic Ward colon tumors were treated with CBLB502 (0.2 mg/kg) was stered by i.p. once a day for three days.

Figure 20 shows the dynamics of xenogenic A549—shV and hTLR5 tumor growth in athymic nude mice after CBLB502 or PBS ol) treatments (days 1, 2, 3). Statistical difference between tumor volumes on days 2, 4, 6 and 8 observed in A549—shV tumors (p<0.05), n=9—14. Right figure demonstrates NF—kB dependent induction of luciferase reporter expression in A549—shV and A549—shTLR5 in response to CBLB502 treatment.

Figure 21 shows the dynamics of H1299 (control) and H1299—TLR5 tumor growth in athymic nude mice after CBLB502 or PBS (control) treatments (days 1, 2, 3), n=6. Right figure demonstrates IL—8 production in response to CBLB502 treatment as indicative of TLR5 on in H1299—TLR5 cells.

Figure 22 shows that the bladder strongly responds to 2.

Figure 23 shows that CBLB502 treatment delays tumor appearance and growth in , even in tumors that do not express TLR5.

Figure 24 shows CBLB502 protection from Fas mediated hepatotoxicity.

Figure 25 shows that the liver is protected from TNFOL and LPS toxicity by 2.

Figure 26 shows that 2 protects the lungs from TNF and LPS toxicity.

Figure 27 shows that CBLB502 protects mice from legal oral administration of Salmonella.

Figure 28 shows that irinotecan tes the mor effect of flagellin (CBLBSOZ).

DETAILED DESCRIPTION The inventors have made the surprising discovery that the provision of a Toll—Like Receptor (TLR) agonist, such an agonist of TLR5 like flagellin, can effectively t the growth of and reduce cancer cells, even when the cells do not express TLRS. The TLR agonist may be particularly useful in treating liver, bladder, lung, and intestinal cancers, whether primary or metastatic, as well as cancer affecting other TLRS—positive tissues. The TLR agonist can also be used to treat cancers that originate in s other than the liver, bladder, lung, intestinal, and other TLRS—positive tissues, but metastasize to these tissues. Even though the metastatic cancer cells do not express TLRS, the cancer may nonetheless be treatable with the TLR agonist when the cancer has asized to xpressing tissues such as the liver. While not being bound by theory, the idea implemented in this invention is that TLR agonists effectively reduce or kill cancer cells affecting a tissue that has a strong innate immunity , thereby ing the need for any pre—existing expression of TLR5 in the cancer cells. Unexpectedly, by providing a TLR agonist, the innate immune system is sufficiently triggered so as to treat cancers that are devoid of TLR5 expression. Thus, TLRS does not need to be provided to the cancer cells in order for the TLR agonist to ively reduce or kill cancer cells.

The inventors have also made the surprising discovery that a TLR agonist can protect the liver from a liver toxicity. For example, death ligands and activators of FAS—mediated apoptosis, such as FAS ligand and anti—FAS agonistic antibodies, can induce does—dependent hepatotoxicity. stering the TLR agonist can protect the liver t such toxicities. This unexpected property of TLR agonists allows it be combined with FAS agonists or TNF for cancer treatment, such that the adverse of effects of the FAS agonist or TNF are reduced or prevented. 1. Definitions.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms 4‘ 77 4‘ a, an” and “the” include plural referents unless the context clearly dictates otherwise.

For recitation of c ranges herein, each intervening number there between with the same degree of precision is explicitly plated. For e, for the range of 6—9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 60—70, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.

“Administer” may mean a single dose or multiple doses of an agent or agent.

“Analog” may mean, in the context of a peptide or polypeptide, a peptide or polypeptide comprising one or more non—standard amino acids or other structural variations from the conventional set of amino acids.

“Antibody” may mean an antibody of classes IgG, IgM, IgA, IgD or IgE, or fragments, or derivatives thereof, including Fab, F(ab’)2, Pd, and single chain dies, diabodies, bispecific antibodies, bifunctional antibodies and derivatives thereof. The antibody may be a monoclonal antibody, polyclonal antibody, affinity purified antibody, or es thereof which exhibits sufficient binding specificity to a desired epitope or a sequence derived therefrom. The antibody may also be a chimeric dy. The antibody may be derivatized by the attachment of one or more chemical, peptide, or polypeptide moieties known in the art. The antibody may be conjugated with a chemical moiety.

A “derivative” may mean a peptide or ptide different other than in primary structure (amino acids and amino acid analogs). Derivatives may differ by being glycosylated, one form of post—translational modification. For example, peptides or polypeptides may exhibit glycosylation patterns due to expression in heterologous s. If at least one biological ty is retained, then these peptides or polypeptides are derivatives according to the invention. Other derivatives may include fusion peptides or fusion polypeptides having a covalently modified N— or inus, PEGylated peptides or polypeptides, peptides or polypeptides associated with lipid moieties, ted peptides or polypeptides, es or ptides linked via an amino acid side—chain functional group to other peptides, polypeptides or chemicals, and additional cations as would be understood in the art.

A “fragment” may mean a portion of a reference peptide or polypeptide.

A “homolog” may mean a peptide or polypeptide sharing a common evolutionary ancestor.

A “leader sequence” may be a nucleic acid encoding any peptide sequence that is linked and translated with a peptide or polypeptide of interest to allow the peptide or polypeptide of interest be ly routed through a eukaryotic cell’ s endoplasmic reticulum and Golgi complexes for the purposed of extracellular secretion from the cell’s membrane. The leader peptide sequence may be derived from alkaline phosphatase. The leader sequence may have a DNA sequence comprising atgctgctgctgctgctgctgctgggcctgaggctacagctct ccctgggc.

A “liposome” may mean a tiny bubble (vesicle) made out of the same material as a cell membrane. A liposome be filled with drugs and used to deliver drugs for cancer and other diseases. A liposome may be filled with a vector. A liposome membrane may be made of olipids, which are molecules that have a head group and a tail group. The head of the me may be ted to water, and the tail, which is made of a long hydrocarbon chain, is repelled by water. The tails may be ed by water, and line up to form a surface away from the water. The lipids in the plasma membrane may be chiefly phospholipids like phosphatidylethanolamine and phosphatidylcholine. Liposomes may be composed of naturally— derived phospholipids with mixed lipid chains (like egg phosphatidylethanolamine), or of pure surfactant components like DOPE (dioleoylphosphatidylethanolamine).

A “peptide” or “polypeptide” may mean a linked ce of amino acids and may be natural, synthetic, or a modification or ation of natural and synthetic.

“Substantially identical” may mean that a first and second amino acid sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,or 99% over a region of 10, , 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 amino acids .

“Treating,” “treatment,” or “to treat” each may mean to alleviate, suppress, repress, eliminate, prevent or slow the appearance of symptoms, clinical signs, or ying pathology of a condition or disorder on a temporary or ent basis. Preventing a condition or disorder involves administering a agent of the present invention to a subject prior to onset of the e.

Suppressing a condition or disorder involves administering a agent of the present invention to a t after induction of the condition or disorder but before its clinical appearance. Repressing the condition or disorder involves administering a agent of the present invention to a subject after al appearance of the disease.

A “variant” may mean means a peptide or polypeptide that s in amino acid sequence by the insertion, deletion, or conservative tution of amino acids, but retain at least one biological activity. Representative examples of “biological activity” include the ability to bind to a toll—like receptor and to be bound by a specific antibody. Variant may also mean a n with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar ties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. M01. Biol. 157:105—132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar athic indexes can be substituted and still retain protein function. In one aspect, amino acids having athic indexes of i2 are substituted. The hilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological on. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the st local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. US. Patent No. 4,554,101, orated fully herein by reference. Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art.

Substitutions may be performed with amino acids having hydrophilicity values within i2 of each other. Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with ical on are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other ties.

A “vector” may mean a nucleic acid sequence containing an origin of replication. A vector may be a plasmid, a yeast or a mammalian artificial chromosome. A vector may be a RNA or DNA vector. A vector may be either a self—replicating extrachromosomal vector or a vector which integrates into a host genome. 2. Toll-like Receptor Agonist Provided herein is a TLR agonist. The TLR agonist may be a PAMP, which may be conserved lar product derived from a pathogen. The pathogen may be a Gram—positive ium, Gram—negative bacterium,, fungus, or virus. The TLR agonist may be a damage— associated lar pattern (DAMP) ligand, which may be an endogenous molecule released from injured or dying cells. A DAMP or PAMP may initiate an immune se through TLR signals and t adapter molecules within the cytoplasm of cells in order to propagate a signal.

The TLR agonist may be an agonist for the TLR, which may be a ligand from the following in Table 1: Table l TLRs and Ligands TLR Ligand DAMP Ligand PAMP TLRl Triacyl lipoproteins TLR2 Heat Shock proteins Peptidoglycan HMGBl (high mobility group Lipoprotein box oterin) ichoic acid Zymosan TLR3 Self dsRNA Viral dsRNA TLR4 Heat shock proteins Heat shock ns Fibrinogen Lipopolysaccharides Heparan sulfate RSV fusion protein Fibronectin MMTV (Mouse mammary tumor virus) envelope proteins Hyaluronic acid Paclitaxel HMGB l TLRS flagellin TLR6 Lipoteichoic acid Triacyl lipoproteins zymosan TLR7/TLR8 Self ssRNA Viral ssRNA TLR9 Self DNA Bacterial and viral DNA TLRlO TLRl l Profilin The TLR agonist may be a fragment, variant, analog, homology or derivative of a PAMP or DAMP that binds a TLR and induces TLR—mediated activity, such as activation of NF—KB activity. The TLR agonsist fragment, variant, analog, homolog, or derivative may be at least 30— 99% identical to amino acids of a TLR—agonist and induce TLR—mediated activity.

The TLR t may target a TLR such as TLR—5. The TLR agonist may be an agonist of TLR—5 and stimulate TLR—5 activity. The TLR agonist may be an anti—TLR5 antibody or other small molecule. The TLR t may be flagellin.

The flagellin may also be a flagellin or flagellin—related polypeptide. The flagellin may be from any source, including a variety of Gram—positive and Gram—negative bacterial species.

The flagellin may be a flagellin polypeptide from any Gram—positive or Gram—negative ial s including, but not limited to, a flagellin polypeptide disclosed in US. Pat. Pub. No. 2003/000044429, the contents of which are fully incorporated herein by reference. For example, the flagellin may have an amino acid sequence from a bacterial species depicted in Figure 7 of US. Patent Publication No. 2003/0044429. The nucleotide sequences ng the flagellin polypeptides listed in Figure 7 of US. 2003/0044429 are ly available at sources including the NCBI Genbank database. The flagellin may also be a flagellin peptide corresponding to an Accession number listed in the BLAST results shown in Fig. 25 of US. Patent Pub. 2003/000044429, or a variant thereof. The flagellin may also be a flagellin polypeptide as sed in US. Patent Appl. Publication No. 2009/0011982, the contents of which are fully incorporated herein. The flagellin maybe any one of a flagellin polypeptide as disclosed in s 3 and 4 herein.

The flagellin may be a fragment, variant, analog, homology or derivative of a flagellin that binds TLR5 and induces TLR5—mediated activity, such as activation of NF—KB activity. A fragment, variant, analog, homolog, or derivative of flagellin may be at least 30—99% identical to amino acids of a flagellin that binds TLR5 and induces TLR5—mediated activity.

The flagellin may be from a species of ella, a representative example of which is S.dublin (encoded by GenBank Accession Number ). The in related—polypeptide may be a fragment, variant, analog, homolog, or tive of M84972, or combination thereof, that binds to TLR5 and s TLR5—mediated activity, such as activation of NF—kB activity. A fragment, variant, , homolog, or derivative of flagellin may be obtained by rational—based design based on the domain structure of Flagellin and the conserved structure recognized by TLR5.

The flagellin may comprise at least 10, 11, 12, or 13 of the 13 conserved amino acids shown in Fig. 2 ions 89, 90, 91, 95, 98, 101, 115, 422, 423, 426, 431, 436 and 452). The flagellin may be at least 30—99% identical to amino acids 1 174 and 418 505 of M84972. Fig. 26 of US. Patent Appl Publication No. 2009/0011982, the contents of which are fully incorporated herein, lists the percentage identity of the amino— and carboxy—terminus of flagellin with known TLR—5 stimulating activity, as compared to M84972.

The flagellin may be the major component of bacterial flagellum. The flagellin may be ed of three domains (Fig. 1). Domain 1 (D1) and domain 2 (D2) may be discontinuous and may be formed when residues in the amino terminus and carboxy terminus are juxtaposed by the formation of a hairpin structure. The amino and carboxy terminus comprising the D1 and D2 domains may be most conserved, whereas the middle hypervariable domain (D3) may be highly le. Studies with a recombinant protein containing the amino D1 and D2 and yl D1 and D2 separated by an Escherichia coli hinge /ECH/CD2) indicate that D1 and D2 may be bioactive when d to an ECH element. This a, but not the hinge alone, may induce IkBa ation, NF—kB activation, and NO and IL—8 production in two intestinal epithelial cell lines. The non—conserved D3 domain may be on the surface of the flagellar filament and may contain the major antigenic epitopes. The potent proinflammatory activity of flagellin may reside in the highly ved N and C D1 and D2 regions (See Figure l).

The flagellin may induce NF—kB activity by binding to Toll—like receptor 5 (TLRS). The TLR may recognize a ved structure that is particular to the flagellin. The conserved structure may be composed of a large group of residues that are somewhat permissive to variation in amino acid content. Smith et al., Nat Immunol. 4: 3 (2003), the contents of which are incorporated herein by reference, have identified 13 conserved amino acids in flagellin that are part of the conserved structure ized by TLRS. The 13 conserved amino acids of flagellin that may be important for TLRS activity are shown in Fig. 2.

Numerous deletional mutants of flagellin have been made that retain at least some TLRS stimulating activity. The flagellin may be such a deletional mutant, and may be a deletional mutant disclosed in the Examples herein. The flagellin may comprise a sequence translated from GenBank Accession number Dl3689 missing amino acids 185—306 or 444—492, or from k Accession number M84973 missing amino acids 179—415, or a variant thereof.

The flagellin may comprise transposon insertions and changes to the variable D3 domain.

The D3 domain may be substituted in part, or in whole, with a hinge or linker ptide that allows the D1 and D2 domains to properly fold such that the variant stimulates TLRS activity.

The variant hinge elements may be found in the E. coli MukB protein and may have a sequence as set forth in International Application No. PCT/USlO/Sl646, filed on October 6, 2010, the contents of which are orated herein by reference.

The flagellin as described above may further comprise a leader sequence. The flagellin further sing a leader sequence may be CBLBSOZS. 3. Agent This invention also relates to an agent comprising a therapeutically effective amount of a TLR agonist. The agent may be a ptide. The agent may also be a . The vector may comprise a nucleic acid encoding the TLR agonist. The vector may be capable of transducing ian cells. The vector may be delivered into a ian cell by a virus or liposome d vector system. The virus vector system may be an adenovirus or a cytomegalovirus.

The agent may be a liposome harboring the vector. The liposome maybe capable of transducing mammalian cells and delivering the vector for expression.

The agent may be a drug formulation that activates a TLR, thereby exposing tumor or infected cells to the host immune system imitating the situation of a massive penetration through the intestinal wall. The agent may be delivered atically in solution for administration such as intramuscularly. The agent may be a drug formulation that expresses the TLR agonist in the form of a nano—particle, which may carry a functional agonist to the cell surface of a mammalian cell.

The agent may be a pharmaceutical agent comprising the drug formulation described above, which may be produced using s well known in the art. The agent may also comprise a coagent.

The vector may comprise a nucleic acid encoding flagellin. The vector may be capable of expressing flagellin using a strong promoter. The expression vector may further comprise a leader sequence cloned upstream of the gene encoding the TLR agonist. The drug formulation may be an adenovirus sing: the TLR agonist, delivered systematically in solution for stration, such as intramuscularly; or the TLR agonist, expressed in the form of nano—particles carrying functional TLR agonist, such as flagellin, which may be d from CBLB502, on their surface. The nano— particle may be on the basis of a bacteriophage T7, or fully formed to retain its biological activity. The nano—formulation may provide for dose—dependent, NF—KB—responsive reporter activation, and may result in cell alization by endocytosis for effective zation ch (Mobian AP—A). 3. Administration Administration of the agents using the method described herein may be systemically, orally, parenterally, sublingually, ermally, rectally, transmucosally, topically, via inhalation, via buccal administration, or combinations thereof. Parenteral administration includes, but is not limited to, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, and intraarticular. Administration may also be subcutaneous, intravenous, via intra—air duct, or intra—tumoral. For veterinary use, the agent may be administered as a suitably acceptable formulation in accordance with normal veterinary practice.

The veterinarian can readily determine the do sing regimen and route of administration that is most riate for a particular . The agents may be administered to a human patient, cat, dog, large animal, or an avian.

The agent may be administered as a monotherapy or simultaneously or metronomically with other treatments, which may be a surgery or removal of a tumor. The term taneous” or taneously” as used herein, means that the agent and other treatment be administered Within 48 hours, preferably 24 hours, more preferably 12 hours, yet more preferably 6 hours, and most preferably 3 hours or less, of each other. The term “metronomically” as used herein means the administration of the agent at times different from the other treatment and at a certain frequency relative to repeat administration.

The agent may be administered at any point prior to another treatment including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36 hr, 34hr, 32hr, 30hr, 28 hr, 26hr, 24hr, 22hr, 20hr, 18 hr, 16hr, 14hr, 12hr, 10hr, 8hr, 6hr,4 hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., mins, 10 mins, 9 mins, 8 mins, 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins.

The agent may be administered at any point prior to a second treatment of the agent including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36hr, 34hr, 32hr, 30hr, 28hr, 26hr, 24hr, 22hr, 20hr, 18hr, 16hr, 14hr, 12hr, 10hr, 8hr, 6 hr, 4 hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., 15 mins., 10 mins., 9 mins., 8 mins., 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins.

The agent may be administered at any point after another treatment including about 1min, 2 mins., 3 mins., 4 mins., 5 mins., 6 mins., 7 mins., 8 mins., 9 mins., 10 mins., 15 mins., mins., 25 mins., 30 mins., 35 mins., 40 mins., 45 mins., 50 mins., 55 mins., 1 hr, 2 hr, 3 hr, 4 hr, 6hr, 8hr, 10hr, 12hr, 14hr, 16hr, 18 hr, 20hr, 22hr, 24hr, 26hr, 28 hr, 30hr, 32hr, 34hr, 36 hr, 38 hr, 40 hr, 42 hr, 44 hr, 46 hr, 48 hr, 50 hr, 52 hr, 54 hr, 56 hr, 58 hr, 60 hr, 62 hr, 64 hr, 66 hr, 68 hr, 70 hr, 72 hr, 74 hr, 76 hr, 78 hr, 80 hr, 82 hr, 84 hr, 86 hr, 88 hr, 90 hr, 92 hr, 94 hr, 96 hr, 98 hr, 100 hr, 102 hr, 104 hr, 106 hr, 108 hr, 110 hr, 112 hr, 114 hr, 116 hr, 118 hr, and 120 hr. The agent may be administered at any point prior after a second treatment of the agent including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36 hr, 34 hr, 32 hr, 30 hr, 28 hr, 26 hr, 24 hr, 22 hr, 20 hr, 18 hr, 16 hr, 14 hr, 12 hr, 10 hr, 8 hr, 6 hr, 4 hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., 15 mins., 10 mins., 9 mins., 8 mins., 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins. b. Formulation The method may comprise administering the agent. Agents provided herein may be in the form of tablets or lozenges formulated in a conventional manner. For example, tablets and capsules for oral stration may contain conventional excipients may be binding agents, fillers, lubricants, disintegrants and g agents. Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone. Fillers may be e, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol. ants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica. Disintegrants may be potato starch and sodium starch glycollate. Wetting agents may be sodium lauryl sulfate. s may be coated ing to methods well known in the art.

Agents provided herein may also be liquid formulations such as aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. The agents may also be formulated as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain additives such as suspending agents, emulsifying agents, nonaqueous vehicles and preservatives. Suspending agent may be sorbitol syrup, methyl cellulose, glucose/sugar syrup, n, hydroxyethylcellulo se, carboxymethyl cellulose, um stearate gel, and hydrogenated edible fats. Emulsifying agents may be lecithin, sorbitan monooleate, and acacia. Nonaqueous es may be edible oils, almond oil, fractionated coconut oil, oily esters, propylene , and ethyl alcohol. Preservatives may be methyl or propyl p—hydroxybenzoate and sorbic acid.

Agents provided herein may also be formulated as itories, which may contain suppository bases such as cocoa butter or glycerides. Agents provided herein may also be formulated for inhalation, which may be in a form such as a solution, suspension, or emulsion that may be administered as a dry powder or in the form of an aerosol using a propellant, such as dichlorodifluoromethane or trichlorofluoromethane. Agents provided herein may also be formulated as transdermal formulations comprising aqueous or nonaqueous vehicles such as creams, ointments, lotions, pastes, medicated plaster, patch, or membrane.

Agents provided herein may also be ated for parenteral administration such as by injection, intratumor injection or continuous on. ations for injection may be in the form of sions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents including, but not limited to, suspending, stabilizing, and sing agents.

The agent may also be provided in a powder form for reconstitution with a le vehicle including, but not limited to, sterile, pyrogen—free water.

Agents provided herein may also be formulated as a depot preparation, which may be stered by implantation or by intramuscular injection. The agents may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins, or as gly soluble derivatives (as a sparingly soluble salt, for example). c. Dosage The method may comprise administering a therapeutically effective amount of the agent to a patient in need thereof. The therapeutically effective amount ed for use in therapy varies with the nature of the ion being treated, the length of time desired to activate TLR activity, and the ndition of the patient. In general, however, doses employed for adult human treatment typically are in the range of 0.001 mg/kg to about 200 mg/kg per day. The dose may be about 1 mg/kg to about 100 mg/kg per day. The desired dose may be conveniently stered in a single dose, or as multiple doses administered at riate intervals, for example as two, three, four or more ses per day. Multiple doses may be desired, or required.

The dosage may be at any dosage such as about 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, 1 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 225 mg/kg, 250 mg/kg, 275 mg/kg, 300 mg/kg, 325 mg/kg, 350 mg/kg, 375 mg/kg, 400 mg/kg, 425 mg/kg, 450 mg/kg, 475 mg/kg, 500 mg/kg, 525 mg/kg, 550 mg/kg, 575 mg/kg, 600 mg/kg, 625 mg/kg, 650 mg/kg, 675 mg/kg, 700 mg/kg, 725 mg/kg, 750 mg/kg, 775 mg/kg, 800 mg/kg, 825 mg/kg, 850 mg/kg, 875 mg/kg, 900 mg/kg, 925 mg/kg, 950 mg/kg, 975 mg/kg or 1 mg/kg. d. Monotherapy The agent may be administered as a monotherapy, under which the agent is not administered together with any other type of cancer treatment, such as chemotherapy, ion therapy, another biological therapy, or other combination therapies; provided that “monotherapy” may include administration of the agent together with surgical treatment. The agent may be administered in combination with a y, which may be tumor removal. The agent may be administered prior to, together with, or after the surgery. The agent may be administered during the surgery. 4. Method for Treating Cancer Provided herein is a method for treating cancer, which may be present in a tissue that expresses a TLR such as TLR5, by administering to a mammal in need thereof the agent. The cancer may be a tumor or a metastatic cancer. The cancer may also be present in liver, bladder, lung, or intestinal tissue, and also may have originated in another type of tissue such as colon, breast, or prostate. The cancer may also be melanoma or a hematological malignancy such as ma. The cancer may also be any cancer that has metastasized to a TLR—expressing tissue, such as liver, lung, bladder, intestine, or other TLR—expressing tissue. The cancer may be a TLR—negative cancer, and thus lack expression of a Toll—Like Receptor. The cancer may lack both endogenous and ous expression of the Toll—Like Receptor. The method may comprise a step of not providing the Toll—Like Receptor to the cancer, which may include not providing the Toll—Like Receptor either exogenously or endogenously. The cancer may lack any and all Toll—Like Receptor expression. a. Toll-Like Receptor The Toll—Like Receptor (TLR) may recognize molecules that are ved lar products derived from pathogens that include Gram—positive, egative bacteria, fungi, and viruses, but are distinguishable from host molecules, collectively referred to as pathogen— ated lar patterns (PAMPs). The TLR may also recognize endogenous molecules released from injured or dying cells, collectively referred to as damage—associated lar n (DAMPs). A PAMP or DAMP may be a TLR agonist as further described below. The TLR may be a fragment, variant, analog, homolog or derivative that recruits adapter molecules within the cytoplasm of cells in order to propagate a signal. The TLR may be from a human or other mammalian s such as rhesus monkey, mouse, or rat. The TLR may be at least 30— 99% identical to a TLR that recruits adapter molecules within the cytoplasm of cells in order to propagate a signal.

The TLR may be one of the between ten and fifteen types of TLR that are estimated to exist in most mammalian species. The TLR may be one of the 13 TLR (named simply TLRl to TLRl3) that have been identified in humans and mice together, or may be an equivalent form that has been found in other mammalian species. The TLR may be one of the ll members (TLRl—TLRl 1) that have been identified in humans.

The TLR may ordinarily be expressed by different types of immune cells, and may be located on the cell surface or in the cell cytoplasm. The TLR may ordinarily be expressed on cancer cells. The TLR may rily be expressed by normal epithelial cells in the digestive system, normal keratinocytes in the skin, alveolar and bronchial epithelial cells, and epithelial cells of the female uctive tract. These cells lining an organ may be the first line of defense against invasion of microorganisms, and TLRs ordinarily expressed in epithelial cells may have a crucial role in the regulation of proliferation and apopto sis.

The TLR may not be sed by the cancer cells. The TLR—negative cancer cells may not express any TLR mRNA, may not express any TLR protein, or may not express any functional TLR protein. The TLR protein may not function due to reduced ability to bind a TLR ligand or reduced ability to transmit ream signals triggered by ligand binding. The TLR— negative cancer cells may also have reduced levels of TLR mRNA, protein, or TLR function.

The reduction may be 100%, or by more than 99.9%, 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, or 50%, as ed to a normal cell from the tissue from which the cancer cell originated, or as compared to another, known TLR—expressing cell type. The TLR— expressing cell may be a normal cell or a tumor cell, such as a tumor cell line or tumor xenograft.

The TLR ordinarily expressed on cancer cells may upregulate the NF-KB cascade and produce anti—apoptotic proteins that bute to ogenesis and cancer cell proliferation.

Four adapter molecules of TLRs are known to be involved in signaling. These proteins are known as myeloid differentiation factor 88 (MyD88), Tirap (also called Mal), Trif, and Tram.

The adapters activate other molecules within the cell, ing n protein kinases (IRAKl, IRAK4, TBKl, and IKKi) that amplify the signal, and ultimately lead to the induction or ssion of genes that orchestrate the inflammatory response. TLR signaling pathways during pathogen recognition may induce immune reactions via extracellular and intracellular pathways mediated by MyD88, nuclear factor light—chain—enhancer of activated B cells (NF-KB), and mitogen—associated protein kinase (MAPK). In all, thousands of genes are activated by TLR signaling, and collectively, the TLR constitute one of the mo st pleiotropic, yet tightly regulated gateways for gene tion.

TLRs together with the Interleukin—l receptors form a receptor amily, known as the “Interleukin—l Receptor/Toll—Like Receptor Superfamily.” All members of this family have in common a so—called TIR (Toll—IL—l receptor) domain. Three subgroups of TIR domains may exist. Proteins with subgroup I TIR domains are receptors for interleukins that are produced by macrophages, monocytes and dendritic cells and all have extracellular globulin (Ig) domains. ns with subgroup II TIR domains are classical TLRs, and bind directly or indirectly to molecules of microbial origin. A third subgroup of proteins containing TIR domains (III) consists of adaptor proteins that are exclusively cytosolic and mediate signaling from proteins of subgroups l and 2. The TLR may be a fragment, variant, analog, homolog or derivative that retains either a subgroup I TIR domain, subgroup II TIR domain, or subgroup III TIR domain.

The TLR may function as a dimer. For example, gh most TLRs appear to function as homodimers, TLR2 forms heterodimers with TLRl or TLR6, each dimer having a different ligand specificity. The TLR may also depend on other co—receptors for full ligand sensitivity, such as in the case of TLR4’s recognition of LPS, which requires MD—2. CD14 and LPS Binding Protein (LBP) are known to facilitate the presentation of LPS to MD—2. (1) TLRl The TLR may be TLRl, which izes PAMPs with a specificity for gram—positive bacteria. TLRl has also been ated as CD281. (2) TLRS The TLR may be Toll—Like Receptor 5. The protein encoded by the TLRS may play a fundamental role in pathogen recognition and activation of innate immunity. TLRS may recognize PAMPs that are sed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. TLRS may recognize bacterial flagellin, a principal component of bacterial flagella and a nce factor. The activation of the TLRS may mobilize the nuclear factor NF-KB and stimulate tumor necrosis —alpha production. (3) Cancer type The cancer may be a y cancer or a metastatic cancer. The primary cancer may be an area of cancer cells at an originating site that becomes clinically detectable, and may be a primary tumor. In contrast, the metastatic cancer may be the spread of a disease from one organ or part to another non—adjacent organ or part. The metastatic cancer may be caused by a cancer cell that acquires the ability to penetrate and infiltrate surrounding normal tissues in a local area, forming a new tumor, which may be a local metastasis.

The metastatic cancer may also be caused by a cancer cell that acquires the y to penetrate the walls of lymphatic and/or blood vessels, after which the cancer cell is able to circulate through the bloodstream (thereby being a circulating tumor cell) to other sites and tissues in the body. The metastatic cancer may be due to a process such as lymphatic or hematogeneous spread. The metastatic cancer may also be caused by a tumor cell that comes to rest at another site, re—penetrates through the vessel or walls, continues to multiply, and ally forms another clinically able tumor. The metastatic cancer may be this new tumor, which may be a metastatic (or secondary) tumor.

The metastatic cancer may be caused by tumor cells that have asized, which may be a secondary or metastatic tumor. The cells of the metastatic tumor may be like those in the original tumor. As an example, if a breast cancer or colon cancer metastasizes to the liver, the secondary tumor, while present in the liver, is made up of abnormal breast or colon cells, not of abnormal liver cells. The tumor in the liver may thus be a atic breast cancer or a metastatic colon cancer, not liver cancer.

The metastatic cancer may have an origin from any tissue. The metastatic cancer may originate from melanoma, colon, breast, or prostate, and thus may be made up of cells that were originally skin, colon, breast, or prostate, respectively. The metastatic cancer may also be a logical malignancy, which may be lymphoma. The metastatic cancer may invade a tissue such as liver, lung, bladder, or intestinal. The invaded tissue may express a TLR, while the metastatic cancer may or may not s a TLR. b. Combination The method may also se co—administration of the TLR agonist with an anti—cancer therapy. The anti—cancer therapy may be FAS ligand, a FAS agonistic dy, TNFOL, a TNFOL agonistic antibody, TRAIL, or a TRAIL agonistic antibody. The TLRS agonist may be used to sensitize the cancer to the anti—cancer therapy. The method may also be ed with other methods for treating cancer, including use of an immunostimulant, cytokine, or herapeutic. The immunostimulant may be a growth hormone, prolactin or vitamin D.

. Method of reducing cancer recurrence Also provided herein is a method of reducing cancer recurrence, comprising administering to a mammal in need thereof a TLR agonist. The cancer may be or may have been present in a tissue that either does or does not s TLR, such as TLRS. The cancer, tissue, TLR, mammal, and agent may be as described above. The method may also prevent cancer recurrence. The cancer may be an oncological disease.

The cancer may be a dormant tumor, which may result from the metastasis of a cancer.

The dormant tumor may also be left over from surgical removal of a tumor. The cancer recurrence may be tumor th, a lung metastasis, or a liver metastasis. 6. Mammal The mammal may have a fully—functional immune system, and may not be immunocompromised. The mammal may also have a level of immunity that is equivalent to the level sufficient to make the mammal eligible for a first or second round a chemotherapy. The mammal may not have a low white blood cell count, which may be chemotherapy—induced. The low white blood cell count may be caused by the loss of healthy cells during chemotherapy. The loss may be an expected side effect of a herapy drug. The low white blood cell count may be a severe immunosuppression caused by chemotherapy. The low white blood cell count may compromise the antitumor effect of the agent. The low white blood cell count may be ed 7— 14 days after a chemotherapy treatment.

The mammal may have a white blood cell count that is within a normal range. The mammal may also have a white blood cell count that is indicative of mild immunosuppression.

The mammal may have not received chemotherapy treatment for 7— 14 days, or at least 14 days.

The mammal may also have total white blood cell count of at least 3000 or 3500 cells/ml of whole blood; a ocyte count of at least 1800 or 2100 cells/ml of whole blood; or an albumin level of at least 3.0 or 3.5 g/ 100 ml of whole blood. The white blood cell count, granulocyte count, or albumin level may also fall within +/— 5%, 10%, 20%, 30%, 40%, or 50% of these levels. 7. Method of protecting liver As sed above, anti—cancer ents that trigger apoptosis through FAS, TRAIL, and TNFOL death receptor signaling, such as death ligands, can cause severe liver toxicity. Thus, the use of molecules such as FAS, TRAIL, and TNFOL as anti—cancer treatments has been limited, despite the efficacy of these molecules in targeting cancer cells. Accordingly, also provided herein is a method of protecting liver tissue in a mammal from the effects of a liver toxicity. The liver may be protected by administering the agent to the mammal. The death receptor signaling agonist may be FAS, TRAIL, or TNFOL. The death ligand may be a liver toxicity. The FAS, TRAIL, or TNFOL may be used as an anti—cancer agent.

The liver toxicity may also be a Salmonella infection, which may be from Salmonella typhimurium. The agent may also be used to protect against liver toxicity that may be FAS— mediated. The toxicity may also be FAS ligand, a FAS tic dy, TNFOL, acetaminophen, alcohol, a viral infection of the liver, or a chemotherapeutic agent. The agent may be administered to the mammal.

Example 1 An agonist of TLR5 protects liver from hepatotoxicity CBLB502, which is a pharmacologically optimized TLR5 agonist, is a powerful radioprotectant due to, at least in part, inhibition of apoptosis in radiosensitive s. CBLB502 was tested for liver protection from Fas—mediated apoptosis. The following examples demonstrate that upon stimulation with CBLB502 the TLRS pathway is active in liver hepatocytes of mice and humans g to NF—kB—dependent induction of genes encoding anti— apoptotic ns. Pretreatment of mice with CBLB502 protected them from lethal doses of Fas agonistic antibodies, reduced Fas—induced elevation of liver enzymes in the blood, caspase activity in liver extracts and preserved liver tissue integrity. 2 did not protect tumors in eic melanoma and colon carcinoma mouse models. These observations support the use of Fas agonists for cancer treatment under the protection of a TLRS agonist, such as CBLB502.

NF—kB response was compared in different organs after administration of TLR5 agonist CBLB502 and TLR4 agonist LPS, another known activator of NF—kB. CBLB502 was found to induce fast direct activation of NF—kB in hepatocytes, while LPS activation of NF—kB in hepatocytes was mediated through different types of cells. The following data thus also demonstrate that pre—treatment with CBLB502 can reduce Fas—mediated hepatotoxicity during anti—cancer therapy in mice. The approaches described below are based on the increasing the resistance of normal tissues to damaging side effects through activation of NF—kB ing by toll—like receptor—5 (TLRS) agonist CBLB502 derived from flagellin of Salmonella urium. 1. Determination of NF-k activation in vivo in response to TLR4 and TLR5 agonists.

NF—kB response was investigated in different organs of mice to TLRS agonist CBLB502 in comparison with bacterial LPS acting through TLR4. NF—kB dependent luciferase reporter Xenogen mouse model in which luciferase transgene is expressed under the control of NFkB— dependent natural promoter of lkBot gene (Zhang N, et al, 2005). Upon stration of NFkB— ting agents, luciferase activity was sed in cells and tissues that d to a given agent. Using noninvasive Xenogen imaging system and ex vivo luciferase reporter assay, detected strong activation of NF—kB in liver of mice was detected 2 hours after so injection of CBLB502 (Figure 7A). The quantitative analysis of NF—kB activation in different organs revealed that in comparison with LPS, CBLB502 induced much er activation of NF—kB in liver, r high NF—kB activation level in the ine, while less NF—kB activity was found in spleen, bone marrow, kidney and lungs (Figure 7B). The dynamics of NF—kB induced luciferase reporter ty was similar for both TLR agonists with the activation profile g approximately two hours after injection, reduced at the six hour time point and effectively undetectable 24 hours post—injection (Figure 10).

Immunohistochemical staining of mouse liver samples for p65 ocation to the nuclei revealed that CBLB502 directly activated NF—kB in hepatocytes as early as 20 min after injection with no response of Kupffer and elial cells yet (Figure 7C). By 1 h after CBLB502 injection, all liver cells including Kupffer cells and endothelium cells demonstrated nuclear accumulation of p65 suggesting overlap of y and ary effects with subsequent tion of NF—kB by paracrine mechanisms. In st, LPS—activated NF—kB nuclear translocation in hepatocytes occurred significantly later. The activation of NF—kB was observed first in Kupffer and endothelial cells followed by the engagement of hepatocytes about 1 h after LPS administration.

Primary hepatocyte es (murine and human) treated with CBLB502, but not with LPS, demonstrated NF—kB translocation to the nuclei (Figure 7D, E). CBLB502 mediated NF—kB tion was confirmed by NF—kB dependent luciferase expression with murine hepatocyte cell culture, while LPS did not induce NF—kB activation in this cells (Figure 11). Small level of NF— kB activation found in LPS—treated hepatocytes was more likely due to contamination of y hepatocyte culture with other stromal liver cells.

These results show that hepatocytes express TLRS but not TLR4 ng 2 to directly activate NF—kB in hepatocytes while LPS initially activates other cell types (immune and/or stromal) and only later indirectly activates hepatocytes as a secondary event. 2. CBLB502 protection from Fas mediated hepatotoxicity As it has been demonstrated, the anti—Fas antibodies can induce dose—dependent hepatotoxicity and rapidly kill mice by ng apopto sis, liver tissue necrosis and hemorrhage (Ogasawara J et al, Nature 1993, Nishimura et al 1997). Thus, NF—kB activation in hepatocytes d by TLRS agonist CBLB502 may protect liver from Fas mediated apoptosis. In NIH— Swiss mice, 4 ug of anti—Fas antibodies (clone J02) injected i.p. induced massive apoptosis, necrosis and hemorrhage in liver (Figure SE, C and D) killing mice within first 1—2 days after dy injections (Figure 8A). Pathomorphological examination of CBLB502—treated mice in dynamics compared to intact control mice showed that their livers had slight vacuolization of the cytes (Figure 12). The examination of mice injected with sub—lethal dose of anti—Fas antibodies (3 ug/ mouse) in dynamics revealed pronounced apoptosis of the hepatocytes around the portal tracts with better preserved cells adjacent to the terminal (central) venues, mo st pronounced at 5 hrs and diminishing with time (12 and 24 hours post—injection). In the livers of mice treated with CBLB502 and anti—Fas antibodies the changes were minimal and the hepatocytes looked close to normal — only slight vacuolization and single apoptotic cells were visible.

CBLB502 injected mice had much less damage to the liver that ed in better overall survival after injections of about than 80% of NIH—Swiss mice when injected 30 min before anti— Fas dies (Figure SA). All mice survived when CBLB502 was ed 2 hours before antibodies. The protection level then declined by 6 hours time—point of pre—treatment.

Two and three ug of anti—Fas antibodies induced only transient liver toxicity in NIH— Swiss mice, caspase 3/7 activation in the liver and alanine aminotransferase (ALT) secretion in the blood (Figure 8E, F). Both tests showed significant reduction of liver damage induced by anti—Fas dies if mice were pre—treated with CBLB502. Interestingly, Balb/c and C57Bl/6 mice appeared to be less sensitive to anti—Fas dies than NIH—Swiss mice. Four ug of anti— Fas antibodies, the lethal dose for NIH—Swiss mice, induced only ent caspase 3/7 activation in BALB/c and C57Bl/6 mice which was successfully prevented by 2 injection 30 min before antibodies e 13).

These data support the esis that TLRS mediated NF—kB activation in hepatocytes can be an indicator and a measure of increased resistance to Fas—mediated toxicity. 3. Suppression of pro-apoptotic and induction of anti-apoptotic factors by CBLB502 in liver.

Caspases 3 and 7 are downstream targets of both intrinsic (mitochondrial) and extrinsic (caspase) Fas—mediated apoptosis signaling. Upon activation of the receptor, first caspase—8 becomes phosphorylated and cleaved leading to activation of mitochondrial apoptotic mechanism acting through cleavage of pro—apoptotic Bid n and cytochrome release (Lou et al 1998). Therefore we examined whether CBLB502 suppresses this mechanism.

Western blot analysis of liver protein extracts for both caspases—8 and Bid demonstrated much less cleavage of these proteins in mice injected with combination of CBLB502 and anti— Fas antibodies in comparison with a single injection of as antibodies (Figure 9A, B).

Consistently, e 8 activation was reduced to a background level, as indicated by using fluorigenic substrate assay (Fig. SF).

The fact that the protection of mice from Fas—mediated hepatotoxicity by 2 is increased with time with maximum g at 30 min—2 hours suggests the existing of pre— conditioning events in hepatocytes. Among the numerous of cytokines and anti—apoptotic factors, the up—regulation of two anti—apoptotic bcl2 family members B and bcl2AlD (Chao and Korsmeyer, 1998, Arikawa et al 2006) was found in livers by RNA array ization 30 min and 2 hours after CBLB502 administration that was confirmed by RT—PCR (Figure 9C).

CBLB502 also quickly induced RNA expression of r anti—apoptotic protein immediate early response protein IER—3 (Figure 9C, IEX—l is an ative name) that was shown suppressing the production of reactive oxygen species and mitochondrial apoptotic pathway (Shen et al 2009). RT—PCR analysis of liver samples revealed the induction of IER—3 RNA expression by CBLB502 already 30 min after administration with significant increase by 2 hours.

Several proteins of MAPK pathway were found up—regulated in livers of CBLB502 treated mice.

It was demonstrated that activation of MAPK pathway in tumors es the resistance of these cells to Fas receptor apoptosis (REF). The up—regulation of Jun, Jun—B and Fos gene expressions directly correlated with mouse survival after anti—Fas antibody injections followed the pre— treatment with 2 suggesting their possible role in CBLB502 mediated protection from Fas hepatotoxicity. 4. Effect of CBLB502 on diated antitumor activity LPS is not a good candidate for al application, since it induces strong inflammation in many organs and can be ly xic through FADD/caspase—8 apoptotic y (REFs). CBLB502 in its turn has been tested in mice, non—human primates and human healthy volunteers and found to be a rather mild inducer of short—lasting inflammation. When evaluating a tissue protecting compounds, there is always possibility that by reducing toxic side effects it can also make tumor cells more resistant and jeopardize the efficacy of antitumor therapy. The in vivo antitumor effect of combination treatment with CBLB502 and anti—Fas antibodies was tested in CT—26 colon carcinoma mouse model of so growing tumors and experimental liver metastases. This tumor model was used in a ly published study applying FasL—expressing S. typhimurium, total attenuated bacteria, to deliver FasL to the tropic tumors and to induce Fas mediated antitumor effect (Loeffler et al 2008). CT—26 tumor cells and A20 ma cells do not express TLR5, as ined by RT—PCR and a NF—kB dependent luciferase reporter assay (Figure 14). Here, tumor—bearing mice were treated with anti—Fas antibodies alone or combination of recombinant CBLB502 given twice 24 hs and l h before a single injection of anti—Fas antibodies (4 ug/ mouse, Figure 9D). The volumes of so growing tumors in treated mice were compared with tumors growing in the intact mice. CT—26 tumors were found to be rather resistant to the toxic but not lethal dose of anti—Fas antibodies (Figure 9D). Pre—treatment with CBLB502 slightly sensitized tumors to anti—Fas antibodies reflecting in —inhibitory tumor response. Fas mediated antitumor effect was tested in the mental model of liver ases induced by intrasplenic injection of luciferase expressing CT—26 tumor cells followed by splenectomy. Hepatic tumor growth was assessed using Xenogen luciferase imaging every 4— 6 days after the treatment. Mice ed free from liver tumor growth were counted at each imaging procedure (Figure 9E). The results demonstrate significant delay of tumor appearance (Figure 9G) and growth in livers by both treatments, anti—Fas antibody alone or given after pre— treatment with CBLB502. The increased sensitivity of TLR5 negative CT—26 tumors to combination treatment with anti—Fas and CBLB502 suggests the activation of antitumor immune response against CT—26 tumors. Indeed, the histochemical analysis of liver sample with CT—26 tumors taken 24 hours after anti—Fas/CBLB502 treatment revealed the accumulation of neutrophils in inside and around of tumor nodules (Figure 9F). Thus, CBLB502 does not protect tumors from anti—Fas antibodies ty and can even ly enhance Fas mediated antitumor effect against CT—26 . The simultaneous protection of normal liver tissue from Fas mediated toxicity may allow increasing the amount of the Fas agonist reaching complete prevention of liver ases and the therapeutic effect against s.c. growing tumors.

Materials and s Mice NIH—Swiss female mice were sed from NCI (Frederick, MD), BALB/c and C57Bl/6 female mice were sed from Jackson Laboratory (Bar , ME). All mice were used in the experiments at the age of 10—14 weeks old. Balb/C—Tg(IKBOt—luc)Xen mice with NF— kB inducible luciferase reporter gene were originally purchased from Xenogen (Alameda, CA) and bred in our domestic colony.

Reagents CBLB502, a bacterial flagellin derivative, was obtained from Cleveland BioLabs, Inc.

Bacterial lipopolysacharide (LPS) from Escherichia coli 055:B5 was purchased from Sigma.

Purified agonistic hamster anti—mouse Fas antibodies, clone J02, were purchased from BD Biosciences.

Analysis of NF-KB activation in vivo using NF—kB reporter mouse model BALB/c—Tg(IKBOt—luc)Xen reporter mice were injected s.c. with CBLB502 (0.2 mg/kg).

The induction of NF—kB by CBLB502 was detected by noninvasive in vivo imaging 2 hours after the treatment (Fig. 1A). Mice were injected with D—luciferin (3 mg/ 100 ul, i.p., a), ately anesthetized with isofluorane and images were taken using Xenogen IVIS Imaging System 100 series. To quantify the results, samples of liver, lungs, kidney, spleen, heart and intestine from NF—kB er mice injected s.c. with 100 ul of either PBS, 2 (0.2 mg/kg) or LPS (1 mg/kg) were obtained 2, 6 and 24 h after injections (Fig. 7B, 10). Tissue samples were covered with lysis buffer containing proteinase inhibitor cocktail (according to manufacture’s recommendation, Calbiochem) to get 100 mg tissue per 1 ml lysis buffer. This was ed by nization and centrifugation at 14,000 rpm for 10 min at 4C. Luciferase activity was measured in 20 ul of samples immediately after adding 30 ul of luciferin reagent (Bright—Glo Luciferase Assay System, Promega). Luciferase activity was normalized per g of the protein extract. Luciferase fold induction was calculated as ratio between average luciferase units in livers of the TLR ligand d mice and that obtained from PBS injected control mice. histochemical staining for p65 translocation.

P65 localization was detected in livers isolated from NIH—Swiss mice injected s.c either with 2 (0.04 mg/kg) or LPS (1 . Control mice were injected with PBS. Tissue samples were obtained 20, 40 and 60 min after the treatments, processed into paraffin blocks. All liver tissues were stained with rabbit polyclonal antibody against NF—kB p65 and rat monoclonal antibody t cytokeratin 8 followed by appropriate secondary fluorochrome—conjugated antibodies (p65 — green, cytokeratin—8 — red). The same staining was performed on the plates with primary mouse hepatocytes isolated from EGTA (0.5mM in PBS) perfused liver tissues of NIH—Swiss mice followed by collagenase digestion and with human hepatocyte culture purchased from (BD Biosciences). Both types of cytes were treated in vitro with CBLB502 (100 ng/ml) or LPS (1 ug/ml) for indicated period of time. Control hepatocytes remained intact. Pictures were taken at X20 magnification (Fig. 7C, D, E). al assay NIH—Swiss mice were injected i.p. with 2, 3, 4, and 5 ug of anti—Fas antibodies in 200 ul of PBS to determine a 100% lethal dose that was found to be 4 ug/ mouse for this mouse strain.

Then CBLB502 (0.04 mg/kg, s.c.) was injected s.c. 30 min, 2 hours and 6 hours before 4 ug of anti—Fas antibodies (i.p.) (Fig. 8A). Usually death from anti—Fas hepatotoxicity occurs during first 1—2 days after antibody injections. Mouse survival was observed and recorded during 30 days.

TUNEL staining of apoptotic cells in liver Apoptosis in the liver of NIH—Swiss mice five hours after injections with 2 (s.c., 0.04 mg/kg) or PBS 30 min before anti—Fas antibodies was detected in paraffin—embedded specimens. tic cells were d by the indirect terminal deoxynucleotidyl transferase mediated deoxyuridine osphate nick end labeling (TUNEL) method with TUNEL POD kit (Roche Applied Science) (Fig. 8B).

Histological assessment of liver morphology Liver specimens were collected from NIH—Swiss mice five hours (Fig. 2C) or in dynamics of 5, 12 and 26 hours (Fig. S3) after anti—Fas antibody injections with or without pre— treatment with CBLB502 (0.04 mg/kg) 30 minutes before antibodies. Mice that were not treated (“intact”) were used as controls. Tissue specimens were fixed in 10% buffered formalin, embedded in paraffin, sectioned and processed with H&E staining.

Histological staining of liver for hemorrhage Paraffin sections were d with antibody t mouse IgG ated with Cy5 [Jackson Immunoresearch, pseudo—colored in purple] and mounted with ProLong Gold anti—fade reagent with DAPI[Invitrogen, blue nuclear stain]. Erythrocytes were fisualized in red channel by red autofluorescence. (Figure 2D). Images were captured under AXioImager Zl fluorescent microscope ) equipped with AXioCam HRc 13 megapixel digital camera using AXio Vision software (rel. 4.6.3) Caspase activation Livers were cut to small pieces and homogenized with a tissue grinder (Bullet Blender, NextAdvance) in the buffer (10mM Hepes, 0.4mM EDTA, 0.2% CHAPS, 2% glycerol), supplemented with 2mM DTT. All steps were med on ice. Liver homogenates were centrifuged for 20 min at 13,000 xg, and supernatant was stored at —20°C. Caspase activities were determined by incubation of liver homogenate ining 50 ug of total protein) with 50 uM of the fluorogenic substrate acetyl—Asp(OMe)—Glu(OMe)—Val—Asp(OMe)—aminomethylcoumarin (Ac—DEVD—amc) (ENZO, iences) in 200 pl cell—free system buffer containing 10 mM HEPES, 0.4mM EDTA, 0.2% CHAPS, 2% glycerol and 2 mM DTT. The e of fluorescent amc was measured after at time 0 and 2 hours of incubation at 37°C by fluorometry (Ex: 355, Em: 485) (Victor3, PerkinElmer). Data are shown as the difference between twp and zero hours (Figure SE).

Detection of alanine—aminotransferase (ALT) in the serum of anti—Fas antibody —treated mice with and without CBLB502 injections iss mice (3 per group) were ed s.c. with 1 ug CBLB502 30 min before anti— Fas antibodies. The alanine aminotransferase (ALT) presence in mouse serum was ined using commercial enzyme assays according to the manufacturer’s instructions (Stanbio Laboratory, Boerne, TX, USA). Absorbance at 340nm was ed at 60 second interval (AA/minute). (Figure SF) n blot analysis Total protein was ed from treated and untreated mouse liver using RIPA buffer —Aldrich St. Louis, MO) supplemented with protease inhibitor cocktail (Sigma—Aldrich St.

Louis, MO). The protein extracts were separated by electrophoresis in denaturing 4 to 20% polyacrylamide Novex gels (Invitrogen, Carlsbad, CA) and transferred to nylon polyvinylidene difluoride (PVDF) membranes (Immobilon—P, Millipore Billerica MA). The following antibodies were used: Caspase—8 antibody (Calbiochem, Darmstadt, Germany), ID (AbCam, Cambridge MA). Horseradish peroxidase (HRP)—conjugated secondary anti—rabbit and anti— mouse antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

(Figure 9A and 9B) RNA analysis Total RNA was extracted from treated and untreated mouse livers using TRIzol reagent according to manufacturer instructions (Invitrogen, Carlsbad, CA). To eliminate any eventual contamination with genomic DNA, isolated RNAs were treated with DNaseI (Invitrogen, Carlsbad, CA). cDNAs were synthesized by using SuperScriptTM II Reverse Transcriptase and oligo(dT)12—18 primer (Invitrogen, Carlsbad, CA), according to manufacturer instructions. RNA expression of BchAlB, BchAlD, IER—3, Fos, Jun and JunB genes in livers of intact mice and treated with 2 and LPS for 30 min and 2 hours was detected by RT—PCR. GAPDH was used as a control to monitor the induction of gene expression. The primers were designed using ene software AR, Inc., Madison, WI) and then UCSC Genome Browser In— Silico PCR website was used to check for locating primers. Primers ic for the IER3 gene (GenBank Accession No. NM_l33662.2) (sense 5’—ACTCGCGCAACCATCTCCACAC—3’ and antisense 5’—CTCGCACCAGGTACCCATCCAT—3’), Bcl2AlB gene nk Accession No.

NM_007534.3) (sense 5’—TAGGTGGGCAGCAGCAGTCA-3’ and antisense 5’- CTCCATTCCGCCGTATCCAT—3’), Bcl2AlD gene (GenBank Accession No. NM_007536.2) (sense 5’—TCTAGGTGGGCAGCAGCAGTC—3’ and antisense 5’— CCGTATCCATTCTCC—3’), Jun (GenBank Accession No. NM_01059l.2) (sense 5’— TGAAGCCAAGGGTACACAAGAT—3’ and antisense 5’— CCAAACAAACAAACAT—3’), Fos (GenBank Accession No. NM_010234.2) (sense ’—GAGCGCAGAGCATCGGCAGAAG—3’ and antisense 5’— TTGAGAAGGGGCAGGGTGAAGG—3’), JunB (GenBank Accession No. NM_0084l6.2) (sense 5’—AGCCCTGGCAGCCTGTCTCTAC—3’ and antisense 5’— GTGATCACGCCGTTGCTGTTGG—3’) and GAPDH gene (sense 5’— ACCACAGTCCATGCCATCAC—3’ and antisense 5’-TCCACCACCATGTTGCTGTA-3’) were used. ication of cDNA was done for 20—30 cycles using specific primer pairs for each gene (Figure 3C).

Experimental therapy of CT—26 tumor—bearing mice The effect of CBLB502 on the sensitivity of tumors to anti—Fas antibodies was analyzed using two models of ic colon adenocarcinoma CT—26 tumor: 1) CT—26 s.c. g tumors, and 2) Experimental liver metastatic model of CT—26 tumors. CT—26 cells were transduced with lentiviral vector carrying luciferase gene under CMV promoter for constitutive expression of luciferase. Tumors were d by s.c. injections of CT—26 tumor cells (2.5x105/ 100 ul) in both flanks of BALB/c mice. When the tumors reached about 4—5 mm in diameter, the mice were randomly divided into three groups and treatment was initiated. One group of mice was ed i.p. with anti—Fas antibodies (4 ug/mouse), another was treated with CBLB502 (l ug/mouse) 24 h and l h before anti—Fas dy injection (4 ug/mouse). Control mice (‘intact’) received PBS injections s.c. and i.p. in replace of CBLB502 and antibodies. Tumor volumes were measured every second day using calipers and calculated by formula: V=H/6*a2*b, where a<b. Survival was followed for 2 weeks when ment was terminated due to large tumors in the control group (Fig. 9D). Statistical difference n tumor volumes was estimated using ANOVA one—way analysis of ces (p<0.05). For the development of liver tumor growth, CT—26 tumor cells (2x105 /50 ul) were injected directly into spleen followed by splenectomy 5 min later. Mice were treated with anti—Fas antibodies and combination of CBLB502 with antibodies the same way as described for s.c. tumors starting on day 5 after tumor cell inoculation. Noninvasive bioluminescent imaging of mice anesthetized with isoflurane and injected with D—luciferin (3 mg/ 100 ul, i.p.) was performed using Xenogen IVIS Imaging System 100 series on the days 14, 17, 22 and 28 after tumor cell injection. Mice were sacrificed when tumor growth in liver was ined. Statistical comparison of liver tumor—free curves was done using log—rank l—Cox) test (p<0.05) (Fig. 9G).

Example 2 Antitumor activity of CBLB502 on colon HCT116 adenocarcinoma s.c. growth in xenogenic model of athymic mice. HCT116 were injected s.c. into 2 flanks of 8 athymic nude mice (0.5x106 /100 ul of PBS) to induce tumors. When tumors became of about 3—5 mm in diameter (by day 6 after injections) mice were randomly distributed into 2 groups, 5 mice for CBLB502 treated group and 3 mice in PBS control group. Suppression of tumor growth was determined in CBLB502 treated mice. Data are shown in Figure 15.

Example 3 Antitumor activity of CBLB502 on 293—TLR5 s.c. tumor growth in xenogenic model of athymic mice. Tumor cells were ed s.c. into 2 flanks of 10 athymic nude mice (2x106 /100 ul of PBS) to induce . When tumors became of about 3—5 mm in diameter (by day 7 after ions) mice were randomly distributed into 2 groups, 5 mice for CBLB502 treated group and mice in PBS control group. Suppression of tumor growth was found in CBLB502 treated mice.

Data are shown in Figure 16.

Example 4 Antitumor activity of CBLB502 on A549 adenocarcinoma s.c. growth in xenogenic model of athymic mice. The original A549 cells (ATCC, CLL—185) were injected s.c. into 2 flanks of 8 athymic nude mice (0.5x106 /100 ul of PBS) to induce tumors. When tumors became of about 3—5 mm in diameter (by day 6 after injections) mice were randomly distributed into 2 groups, 5 mice for 2 treated group and 3 mice in PBS control group. A549 tumor— bearing mice were ed with either CBLB502 (1 ug/ mouse) or PBS three times with a 24—hr time interval. In the PBS injected control group of mice, tumor s gradually and rly increased. On the other hand, the CBLB502 injected mice expressed inhibited tumor growth during the first l days after injections and then tumor growth restored. The second round of CBLB502 injections 2 weeks after the first treatment (days 14, 15 and 16) induced analogous tumor growth inhibition for approximately 1—2 weeks before the restart of tumor growth. As a result, by the end of the experiment the sizes of the A549 tumors differed significantly in the two groups of mice, being much smaller in CBLB502 treated vs. PBS treated mice. Data are shown in Figure 17.

Example 5 Antitumor effect of CBLB502 on syngenic orthotopically (s.c.) growing squamous cell carcinoma SCCVII tumors. The rate of SCCVII orthotopic tumor growth in ic C3H mice after CBLB502 or PBS (no treatment) ents (0.1 mg/kg, s.c.days l, 2, 3) to reach 400 mm3 tumor size, n=6—10. The x—axis in Figure 18 represents the amount of days needed for tumors to reach 400 mm3 volume with and t treatment with 2. Data are shown in Figure Example 6 Antitumor activity of CBLB502 in Fischer rats bearing so advanced Ward colorectal carcinoma. CBLB—502 was administered by i.p. once a day for 5 days (0.2 mg/kg x 5 doses) initiated 5 days after tumor transplantation into 4 rats. Control 4 rats received PBS injection as a vehicle control. Tumor weight was measured daily. Complete response (tumor complete disappearance) was observed in 3 rats treated with CBLB502 (Figure 19). The fourth rat in this group had tumor growth similar to rats in the control group.

Example 7 The effect of CBLB502 injections on A549 tumors differing in TLR5 expression (A549— shTLR5 vs. hV). In order to suppress TLR5 expression, A549 cells expressing Firefly luciferase gene under the control of NF— kB er (Cellecta, Mountain View, CA) were transduced with lentiviral pLKOl—puro vector expressing shRNA specific to human TLR5 gene [CCG—GCC—TTG—CCT—ACA—ACA-AGA-TAA-ACT-CGA-GTT-TAT-CTT-GTT-GTA-GGC- AAG—GTT—TTT—G] or control empty vector (shV, Sigma—Aldrich, St. Louis, MO). After puromycin selection, hV and hTLR5 cells were tested for NF—kB activation in se to CBLB502 treatment using luciferase reporter assay according to manufacture protocol (Promega, Cat#E4530, Madison, WI). Then A549—shV and A549—shTLR5 cells (1x106 / 100 ul of PBS) were injected s.c. into 2 flanks of 20 athymic nude mice to induce . Mice bearing s.c. growing A549—shV and A549—shTLR5 tumor xenografts (5 mice per group) were treated with either CBLB502 or PBS acting as control The results demonstrate that the repeated administration of 2 alone led to a reduction in tumor growth rates in the A549—shV (TLR5—expressing) tumor xenografts demonstrating a direct tumor ssive effect of the drug.

As shown for A549 d tumors, this effect was TLR5 dependent since TLR5 own elicited by lentiviral transduction of shRNA against human TLR5 rendered the A549 tumors no longer ive to the direct antitumor effect of CBLB502. Data are shown in Figure 20.

Example 8 The effect of CBLB502 injections on Hl299 tumors ing in TLR5 expression (Hl299—control vs. Hl299—TLR5). In order to induce TLR5 sion, Hl299 cells (originally TLR5 negative) were transduced with lentriviral construct sing human TLR5 gene. The functional activity of TLR5 was checked by IL—8 production in response to CBLB502 treatment.

Then both tumor cell types (lxlO6 /100 ul of PBS) were injected s.c. into 2 flanks of athymic nude mice to induce tumors. Similar to A549 model described above, mice bearing were treated with either CBLB502 or PBS acting as control. The results demonstrate that the repeated administration of CBLB502 alone led to a reduction in tumor growth rates only in Hl299—TLR5 (TLR5—expressing) tumor xenografts demonstrating a direct tumor suppressive effect of the drug.

As shown for the control Hl299 (TLR5—negative) tumor growth was not affected CBLB502 treatment. Data are shown in Figure 21.

Example 9 This example demonstrates that bladder tissue is a strong responder to 2. The experiment was conducted as described as described above for liver tissues. NF—kB dependent luciferase expression in liver, small intestine (ileum part), colon, spleen, kidneys, lungs and heart was assessed in the reporter mice 2 hs after s.c. injections of 100 ul of either PBS, CBLB502 (0.2 mg/kg) or LPS (1 . Luciferase activity normalized per ug of the protein extract was detected in 3 mice in each group. The data are shown in Figure 22.

Example 10 Table 2 shows the spectrum of genes transcriptionally activated by CBLB502 in target organs of mice (bladder results are shown). Genes that are strongly upregulated in rs of mice treated with CBLB502, l and 3 hrs post—injection, are clustered according to their function.

The largest group consists of chemokines, cytokines and their receptors tive of activation of innate immunity mobilizing mechanisms.

Example 11 CT—26 tumor cells, which do not express TLRS, were injected s.c. into syngenic BALB/c mice to induce tumors. Tumor bearing mice were treated with CBLB502 (0.04 mg/kg, s.c.) given twice 24 hour apart. The volumes of s.c. g tumors in treated mice were ed with tumors growing in the intact mice. Pre—treatment with CBLB502 did not have any effect on tumor growth. Then CT26 tumor growth was tested in the experimental model of liver metastases induced by intrasplenic injection of rase expressing CT—26 tumor cells (Figures 23B and C) and A20 lymphoma cells (Figure 23D) followed by splenectomy. Hepatic tumor growth was assessed using n luciferase imaging every 4—6 days after the treatment. Mice remained free from liver tumor growth were counted at each imaging procedure. The results demonstrate prevention of tumor growth and significant delay of tumor appearance in livers by CBLB502 treatment in both tumor models. The difference between CBLB502 treated and control groups in liver tumor models (B, C, D) is significant (log rank p<0.05). The data are shown in Figure 23.

Example 12 2 protection from Fas mediated hepatotoxicity. A. Survival of NIH—Swiss mice after i.p. injection of 4 ug of anti—Fas antibodies alone or in ation with CBLB502 (1 ug/ mouse) injected 30 min, 2 hours and 6 hours prior antibodies. In parenthesis are the numbers of mice per each treatment. B. Protection of livers from as antibody toxicity. Apoptosis in livers 5 hours after injections of anti—Fas antibodies was ed using TUNEL technique.

Tissue morphology with H&E staining revealed necrotic damage to livers by as antibody injections and protection by CBLB502. hage in liver was detected by erythrocyte infiltration in tissue, mouse IgG control (purple) and DAPI nuclei (blue). Data are shown in Figure 24.

Example 13 Liver protection from TNF—alpha and LPS toxicity. A. Caspases 3/7 were detected 5 hours after injections of TNF—a or LPS and lipis oxidation (indicative of inflammation damage) was detected 24 hours post ion in mice with and t CBLB502 treatment 30 min before TPS/ TNF—a. e activation and lipid oxidation in lungs induced by TNF (l mg/mouse) was prevented by CBLB502 injection. LPS (10 mg/kg) induced damaging effect was completely abolished by CBLB502 injection 30 min before LPS. Data normalized by protein concentration, 24 hours after the treatment, n=3. It was no e activation (5 hours after TNF injections) and much less lipid oxidation (24 hours post—TNF ions as indicative of atory damage) in livers of mice if CBLB502 was injected 30 min before h—TNF. B. lmmunohistochemical analysis (H&E staining) confirmed the preservation of liver integrity by CBLB502 injection before TNF—a. Compared to the intact control, the liver of the TNF—treated mice showed vacuolization of the hepatocytes that is slightly more pronounced periportally and is dose—dependent (more severe in TNF 0.4 mg/mouse). In the livers of mice treated with CBLB502 and TNF 0.2 mg or 0.4 se, the changes were minimal and the hepatocytes were close to normal though slight ization was still visible. Data are shown in Figure 25.

Example 14 Lung protection from TNF—a and LPS ty. Compared to intact control, the lungs of the TNF—treated mice showed reactive proliferation of ar cells, hyperemia titial edema and exudates in alveoli leading to reduction of the air spaces and the alteration was dose— dependent (more severe in TNF 400). In the lungs of mice treated with CBLB502 and TNF 200 ng or 400 ng, the changes were minimal. The morphology was close to normal though slight thickening of alveolar walls was still visible (Figure 26B). It was almost normal level of lipid oxidation (indicative of inflammatory damage) in lungs of mice if CBLB502 was injected 30 min before LPS (10 mg/kg) or h—TNF (0.05 mg/kg) (Figure 26A). Data are shown in Figure 26.

Example 15 Protection of mice from lethal oral Salmonella typhimurium administration by CBLB502 injections. Conditions of the experiments are shown in Figure 27. e 16 This examples trates that irinotecan abrogates the antitumor effect of flagellin.

The data are shown in Figure 28. Fischer rats with s.c. growing syngeneic Ward colon tumors were treated with 2 (0.2 mg/kg), which was administered by i.p. once a day for three days. Irinotecan (200 mg/kg) was injected iv. 30 min after each CBLB502 injection. PBS was used as a vehicle control (Fig. 28A). CBLB502 rescued rats from Irinotecan toxicity with no interference with irinotecan antitumor activity (Fig. 28B). The mor effect of CBLB502, however, was not observed in irinotecan—treated rats (Fig. 28C). This demonstrates that the antitumor effect of CBLB502 requires sufficient innate immunity levels.

TableZ ‘EEEEEEEEEEEEE E‘EEEEEEEEEEEE EEEEEE EEEEEEE EEEEEEEEEEE control flic 1 LPS 1 1 qac prrepnfi 3 lEaca CXCL2 1 4175.5 466.8 4175.5 -1.6 92.4 113.7 cxc110 1 3477.1 751.9 3477.1 5.1 304 18.9 CCL2 1 1460.8 523.5 1450.8 —0.5 247.5 —0.4 cxc11 21.5 21314.9 13985.8 985.8 73.3 18247.5 5458.7 CCL20 1 521.4 15.1 521.4 CXCL2 1 240.2 8.9 240.2 cc17 25.2 3738.3 2575.3 148.3 1.1 554.1 218.3 CCL4 14.6 613.2 3296.7 42.0 28.2 1002 3630.4\ cc13 1.8 74.2 350.5 41.2 CXCL9 11.5 185.5 94.5 15.0 2.8 389.7 481.3 CCL4 11.1 99.3 445.7 8.9 28.2 1002 3530.4 CXCL16 253.2 2048.1 545.5.-. .78. 35.8 524.2 385.1k CXCL15 1 34.5 14.1; E.

CCLS 19 480 558.7 25.3 CCL19 1.9 44.5 35.2 23.5 CXCL12 —5.3 14.9 14.4 14.9 CCL25 25.5 224.5 280.1 8.5 CCL1 1 4.2 CCL11 192.8 616.4 CCL11 149.7 452.1 CCL17 13.7 125.5 3.5 540.1 \\ CCL19 7.5 18.4 CCL2 1 1450.8 523.5 1450.8 CCL20 1 521.4 CCL22 1 3.9 CCL26 1 4.2 CCL28 1 3.7 CCL3 1.8 74.2 CCL4 14.5 513.2 CCL4 11.1 99.3 CCL7 25.2 3738.3 CCL7 12.3 1453.5 CCR3 1 2.3 CCRS 5.9 12.1 CCRS 11.5 22.7 CORE 1 3.8 -4.7 17.5 5.8;\\\ CCRL2 52.7 510.5 CLCF1 4.5 23.2 CNTFR 1 9.1 -1.1 9.1 Table 2 CNTFR 14.5 29.8 21 CX3CL1 216.7 1081.9 328.9; 183.2 1471.3 440.5 CXADR (CAR) 22.2 59.4 52.72 CXCL1 21.6 21314.9 13985.8 cxcuo 1 3477.1 751.9 CXCL15 1 34.5 14.1 CXCL16 30.4 371.9 61.3 CXCL16 263.2 2048.1 546.6 CXCL17 1 7.7 4.5 CXCL2 1 4175.5 466.8; CXCL2 1 240.2 8.93 CXCL9 11.6 185.6 94.53 CXCRS 1.3 4.7 143 FAS 138.7 967.8 288 FAS 396.2 1802.5 730 6g FASL 3.6 10.2 1 FPR2 14.2 96.4 187 0.1 954.1 1765.8§x |ER3 1494.5 12012.4 8339.1 L|F 1 213.4 13.8 LIFR 1 6 DARC 131.2 360.4 277 2.7 87.9 1102.6 2605.8 12.5 CMKLR1 -7.3 8.9 10.4 8.9 0.1 954.1 1765.8“ EBB 21.5 297.3 208.511111 0 .3330: @6933 68.2.8103 |L7R 1.6 24.9 43.8 15.6 |L8RA -2 10.7 3.4 10.7 |L9R 0.5 9.5 3.1 9.5 |L17C 1 887.3 31.8 887.3 LIF 1 213.4 13.8 213.4 |L1RN 1 52.8 45.2 52.8 51.3 729.5 538.5 14.2 Table2 |L1F5 —4.2 8 3.8 8.0 |L1R1 0.1 10 22.1 10.0 |L1R2 51.8 397.6 281.7 7.7 |L10 1 19.5 263 |L1ORA 15.5 34.3 29.55 |L10RB 1.5 14 15.2 11124 -1.2 32.2 10.3 32.2 |L12RB1 14.7 -0.5 13.7 10.9 |L12RB1 7.1 21.7 1113 11.4 111.9 258.5 9.8 |L13RA2 -4.2 12.4 121.7 12.4 |L15 4.8 10.6 8.6% |L15RA 7.4 38.1 195 |L15RA 5.1 24.8 14.35 |L15RA 19.2 47.1 323 1116 1 2 4E |L17A 1 5.4 |L17B -2.5 30.8 -4.5 30.8 mm 1 887.3 -0.2 8.6 1.7 |L17RA 26.1 72.2 |L17RB 0.2 38.1 10 38.1 |L18BP 20 143.7 283 7.2 |L18Rl 57.4 857.8 892.9 14.9 P 1.3 24.3 0.1 18.7 |L18RAP 7.6 18.4 19.15 1119 -0.7 26.7 95.4 26.7 |L1A 1 14.9 43.7 14.9 |L1A 2.8 35.5 72.3 12.7 |L1B 20.7 437.9 1023.3 21.2 |L1RAP 6.1 11.9 5i 111 RL1 1 22.3 13.1 |L1RN 1 52.8 45.2 -2.7 34.4 0.9 |L1RN 1.9 6 2.93 51.3 729.5 538.5 |L1RN 51.5 158.5 118.85 -2.9 10.3 1% |L2RA -5.8 8.7 18.1 8.7 ILZRB 4.8 49 -2.2 10.2 ILZRG 1.2 12.9 3 10.8 ILZORA 4.8 34.2 21 7.1 120103 1.6 6 —1.1 11.9 —3.4 11.9 ILZORB 2.5 8.5 |L21R 1 7.5 5.8 65 65.4§\\\\ |L21R 6.5 13 |L22RA1 1.2 8 |L23A 2.2 10.5 1127 1 5.2 |L28RA 1.6 15.3 |L28RA 134.8 279.3 |L2RG 1 7 |L31RA 1 4.5 IL33 150.4 352.9 \ |L4l1 28.9 1891 46.8 4000 741.7 115 1 2.5 -0.7 9.2 3.4 |L6 1.1 11.8 0.4 12 59.6k |L6RA 37.1 387.1 798.5 10.4 |LF2 0.9 17.4 8 17.4 ILTIFB 0.8 20.5 10.4 20.5 55 55 .5555 AIF1 -5.2 8.3 11 8.3 ARIDSA 25.1 259.4 302.6 10.3 EGR4 1 231.2 CSFZ 1 202.5 0 10.4 4 CD70 1 54.7 0.6 520.2 67.5 AREG 8 1299.1 11.5 692.1 255.8 CSF3-(GCSF) 1 35.4 CSF1 49.7 486 33.1 509.2 397.4 15.4 CSF2 1 202.5 CSF2RB 1.2 6.6 CSF3 1.3 6 CSF3-(GCSF) 1 35.4 CSF3R 1 2.3 EGR1 1824.5 6578.8 EGR2 31.1 224.1 157.4 7.2 EGR3 58.6 1126.3 1120.8 19.2 EGR4 1 231.2 FGF10 3.5 8.8 FGF12 1 5.3 FGF12 4.8 11.7 FGF13 4.9 15.2 FGF15 6.6 18.4 FGF17 1.1 3 FGF22 1.7 13.6 FGF3 1 2.3 FGFBP3 1 6.4 FGFH1OP 11.8 31.7 FGFHZ 11.1 24.6 GDF15 8.5 173.4 HBEGF 72.3 1118.3 |GFBP3 120.1 301.3 NELLZ -4.9 24.9 10.3 24.9 BDNF 0.4 19.2 18.6 19.2 TGFBRl 6.6 73.4 137.8 11.1 NGFR 20.3 177.1 52.3 8.7 888288 88888 13sz 68.6 4.4_ CLEC1A CLEC2D CLEC2E CLEC4D CLEC4E CLEC7A CLECSF9 PGLYRP PGLYRP1 21.7 429.5 28 19.8 PTX3 1 309.8 525.7 \8 PVR 13.8 99.3 31.1 7.2 PVR 52.1 262.7 144 PVR 30.7 95.4 52 PVRL1 40.7 107.6 52 PVRL2 70.7 207.8 96 S100A8 34.5 288.9 32.6: S100A9 23.6 139.9 20 8AA1 2.9 5.7 16 SAA3 125.6 500 1208 ICOSL 25.3 106.7 3 KLRG2 273.2 695.9 KLR|1 2.1 14.5 2888-82 88888 2282888888 8 888888 88 8 8888 8828888888 SFTPD -7.5 23.4 84.8 23.4 SAA3 69.9 3183.4 2571.7 45.5 PGLYRP1 40.8 2012.5 255 49.3 KLRD1 5.8 107.8 171.1 18.6 HCST 26.4 198.3 202.3 7.5 FCGR4 37.6 1168.4 2200.4 31.1 MYD88 75.8 312.2 174 NOD2 5.3 37.6 17.2 2 30.3 7.8 TLFl1 5.1 TLR2 372.6 7545.6 2270.3 20.3 4.5 TLR3 9.1 TLR5 2.0 TLR6 2.804973 0.353293 Table 2 TLFI7 2.5 LY96 332.8 2474.1 1466.9 7.4 |RAK3 109.4 314.9 231 101.8 941.3 1132.4§\\\\\\ |RAK4 1 10.5 3188856883589 338828 ZBPl 27.5 210.1 419.6 7.6 WFDC12 3.8 1134.8 3.3 298.6 SlOOA8 0 897.8 661.5 897.8 510049 -0.7 1021.2 1620.9 1021.2 RSAD2 154 5347.3 3471.3 34.7 REG3G -3.3 857.6 471.2 857.6 MX2 21.9 959.8 671.8 43.8 LYZL4 24.8 215.1 -8.4 8.7 LTF -0.5 272 184 272.0 DMBTl -4.3 69.9 1 69.9 CRP 0.6 210.5 1721 210.5 CH|3L1 6.8 843.8 257.1 124.1 HAMP 1 117.6 -7.2 27.2 8.9 LCN2 7.7 492.4 9.2 1256.1 511.3 CHI3L1 11.8 128.2 6.8 843.8 257.1& DEFB18 -5.7 11.7 -5.4 11.7 DEFBZO -0.5 22.1 22 22.1 DEFB26 2.4 30.1 29.5 12.5 DEFB34 -2.2 7.1 -5.3 7.1 DEFB36 -0.7 8.3 —1.3 8.3 DEFB38 -6.9 7.6 -2.9 7.6 DEFB50 -5.4 8.6 6 8.6 DEFCRS -2.6 10.9 -4.7 10.9 RSl -1.2 8 3.9 8.0 DEFCR-RSlZ —0.7 11.9 16.9 11.9 DEFCR-RSlZ -6 11.6 5.4 11.6 DEFCR—RSZ -2.8 9.4 —3.1 9.4 DEFB23 1 3.5 DEFBBO 1 2.4 DEFBS 7.4 16.4 DEFCR6 3.7 7.6 07 27.4 57.7 CFB 24.2 396 682.4 16.4 ClQL2 -4.5 18.3 12.1 18.3 C9 1 4.2 2.2% -8 15.4 17.8 15.4 CAMP 1.2 7.5 12.45 |RGM1 1 3.6 3.4% 1.2 32.2 -4.3 MX2 20 42.6 91.4; 21.9 959.8 671.8 REGBG 1 81.2 3.9 -3.3 857.6 471.2 WFDC12 1 238.5 —2 3.8 1134.8 3.3:\\ LCN10 -0.7 49.8 50.7 49.8 LCN3 —1.3 36.5 0 36.5 Table 2 CAMP 2.4 56.3 43 23.5 APOM 1 21.7 2.5 21.7 APOOL -8 8.9 -8.2 8.9 ClQL2 -4.5 18.3 12.1 18.3 CD14 570.3 12181.7 2137.5 21.4 CD160 -1.1 70.5 96.2 70.5 CD177 1 5.7 0.3 23.2 3.9§\\\\\ CD177 9.9 110.9 3.6 11.2 CD19 2.1 6.9 CD2OOR1 4.1 2 —4.5 7.6 12.1 7.6 CD207 1.2 5.8 CD207 1 3.1 CD247 2.9 CD27 -2.9 11.3 4.4 11.3 CD274 108 1070.2 398.3 9.9 CD28 | 1.2 2.7 CD209C 2 24.2 93.6 12.1 CD209D -3.6 35.5 54.7 35.5 CD209E -8.5 7.1 11.5 7.1 CD300LB 1 2.7 CD33 13.5 27.4 CD3E 17.2 122.3 21.2 7.1 CD4 1.2 9.3 CD40 52.6 460.8 54.8 1419.4 775.7 CD40 15.2 108.4 15.9 193.1 101.3 CD44 31.3 106.2 -2.6 27.8 19 CD44 13.5 32.8 -1.7 22.8 0.2 CD44 305.7 725.2 171.5 1251.9 596.8§ CD44 66.4 133.3 CD52 1 2.1 CD53 10 20.6 CD6 1 5.5 -2 7.4 17.5&\\ CD6 1 3.3 CD6 3.2 7.2 CD6 6.7 13.1 CD69 4 100.3 9.7 97.2 269.3 CD7 1.3 10.5 8.9 CD70 1 54.7 0.6 520.2 67.5% CD79B 1 3.9 CD80 8.5 31.5 CD80 3.1 7.1 . g CD83 45.7 771.8 486 16.9 CD86 3.2 5.8 -4.3 3.5 59.4 30.3 17.0 CD8B1 -1 30.2 -5.1 30.2 CD96 1 5.3 Table2 3333333333933 33% 3333 “38833033 NEOl 9.8 69.3 .

NFIC 12.3 136.2 297.6 POU2F2 11 161.3 164.9 POU3F1 6.5 140.6 83.1 SBNOZ 54 765.1 860.1 SIRT6 17.7 182.1 195.4 10.3 GTF3C6 4.2 84.2 106.1 20.0 GEMINS 11.3 93.2 157.1 8.2 F|P1L1 —2.1 57.9 10.3 57.9 FAP 5 51.7 2.4 10.3 CHDl 27.5 295.2 529.8 10.7 BACHl 21.7 159 299.5 7.3 BARX2 15.6 234.6 144.6 15.0 ATF3 31.6 690.5 ATF4 43.8 115 BATF 17.2 150.8 21.9 185.7 460.4 BAZ1A 27.6 93.8 CCND2 1.6 7.9 CCNL 30.3 67.6 CCNYL1 30.5 103.3 CDK2 29.1 67.9 CDKS 4 8.8 CDK5R1 24.2 110.2 CDK6 4.1 27.3 CDK7 1.5 3.8 CDKN1A 147.1 374.4 CDKN1A 370.5 730.6 CDKN2B 1231.3 2751.7 EGLNS 406 2015 -1.3 19.3 -4.6§\\\\\\ EGLNB 3.2 11.4 E|F4E1B -2.4 18.9 4.9 18.9 ELF3 #REF! 3525.2 ETS1 1 22.7 FKHL18 63.6 336.2 52.6 431.6 \\\\ FOSB 92.3 738.1 FOSL2 4.6 32.2 0.4 11.7 -0.1 FOSL2 4.7 20.4 6.7 70.5 61 FOXA3 1 13.2 3.2 100.6 0.9% FOXB1 1 3.8 FOXDQ 1 5.6 . §\\\\\\ FOXE1 -0.4 8.8 -2.9 8.8 FOXF2 -1.2 10.3 20.6 10.3 FOXF1A 400.7 960.3 FOX/2 1 2.6 FOXJ3 9.2 20.3 FOXJ3 5.7 12.2 Table 2 ' \N‘x‘g .5 \wxsg 14.1 GADD45A GADD453 ' \“W- GADD45B GADD45G HF1A HWlAN JDP2 JUNB JUND1 MAFF NFATC1 NFATC1 NFATC1 NFATC1 NFATC2 NFATC2 NFE2L2 KLF6 MYCT1 SOX7 SOX9 soxe $§§3$§§§3§i§R 1- \ ‘4 '\ . _ ANKHD1 APBA1 Table 2 APBBMP APHlA NRCZ MRC3 NRC6 BBC3 BCLAF1 BCL1o BCL10 BCL2A1 B BCL2A1C BCL2A1D BCL2A1D BCL2LT BCL2L11 BCL2Lr BCL3 BCLGB BCL9 BCLQL NUPR1 DNASE1L3 1396 125373 DUSP13 DUSP2 DUSP2 DUSP3 DUSP3 DUSPe DUSPs DUSPe DUSP8 MMP2K3 MAP3K2 A4AP3K7 MAP3K8 NMFMK5 §§§§§k34 MAPK11 MAPK15 MAPK1IP1L MAPK6 MAPK8 MAPK8 MAPK8IP3 MAPK8IP3 MAP2K1 MAP3K12 MAP3K4 MAP3K5 MAP3K6 MAPKlO MAPK7 CKMT1 CSNK1G1 DAPP1 DYRK1A P|M1 P|M1 P|M2 P|M2 PLK2 PLKS ITPKC RIPK2 ' {Rx 16.4 531.5 170.4 796 1974.1 1706 i 8.6 53.9 40.6; 28.9 67.5 76 580.4 1978.1 548.9 1582.2 90.4 672 |F|202B 14.6 51.4 Table 2 |F|47 38.6 90.7 IFITMl 3562.3 8026.1 8.1 474 58mm IFITM1 1023 7728.1 4581.7 7.6 |F|TM5 1.3 20.3 -2.5 14.6 -1.9 IFITM6 -1.9 12.1 62.7 12.1 |FNE1 8.5 28 IFNG 1 2.6 |FNGR2 107.1 425.9 |RF5 23.5 52.3 |RF6 23.5 52.3 —5.1 15.4 —4.7m |RF6 23.5 52.3 |RF7 15.4 230.7 207.4 15.0 |RF9 23.5 52.3 PLSCR1 114.6 893.3 PLSCR1 66.9 305.6 SLFN2 18.4 252.7 ISGZOLl 19.9 159.7 166.4 8.0 IGTP 164.5 1836.5 1147 11.2 048583 -3.5 27.8 109.6 27.8 Loc100048583 -3.5 27.8 109.6 20.4 GVINl 45.4 458.2 976.11.11.11.11.11111011.

PSMBQ 15.4 114.6 142.3 7.4 PSMDll 6.1 62.8 0.6 10.3 PSMD3 -5.7 15.5 132.5 15.5 “iawwtinfi‘msosw |BRDC3 177 699 LNX1 1.4 10.9 UBD 17.4 85.8 03702 20.4 60.9 USP2 6.2 15.6 USP23 2.7 8.7 3238.36 -1.8&\\\\ USP25 6.9 15.6 USP37 5.5 19.2 USP38 22.9 45.5 USP42 1 2.9 USP48 4.8 17.1 USP27X -0.9 8.7 —1.5 8.7 USP29 -2.8 7 10.1 7.0 usp37 19 330.9 294.3 17.4 USP43 10.1 108.8 30.8 10.8 USP8 -2.4 27.9 5.3 27.9 USP9X -3 37.8 115.3 37.8 CUL4A 0.5 22.4 6.2 22.4 UBD 13.4 446.1 278.5 33.3 LINCR 24.7 1194.7 109.8 >4 Table2 DTX3L 166.3 1484.1 608.4 8.9 MARCHl 10.5 75.1 134.7 7.2 11111111111 FLNB CCTS 288.6 2407.1 1216.1 8.3 CDC42EP1 13.6 110.1 113.6 8.1 CDC42EP5 2 52.5 48.1 26.3 CEP350 —2.3 54.4 167.6 54.4 ARPC4 19.9 155 138.7 7.8 ARPMl -1.1 10 3.2 10.0 ACTB 3142.5 7089.1 6166 ARC 16.7 320.9 83.63 .

ABLIM3 1 4.8 7.9 #REF! -5.9 17.4 13 17.4 ACTL7B -2.4 13.6 0.9 13.6 ACTR6 -1.4 9.4 28.3 9.4 SCIN 54 597.9 49.63 59.7 1853 14mm TUBA6 1429.6 2863.9 2070 TUBBZB 940.9 2963.8 1731 DUOXA2 1 280.8 11.5 878 25.2 EHD1 131.3 725.6 115.1 808.1 615.6Q 111111.11111111: GPR109A 131.7 4123.4 1185.8 1111: GPRCSA 39.6 421.2 251.8WW106 RAI3 24.4 212.5 117.6 LPAR2 32.4 221.4 LPAR3 129.6 660.7 RGS16 R6516 387.9 372.6 RN01 1.6 11 RN03 157 806.7 GPR84 1 65.4 GNAS —1 267.2 LPAR2 12.3 94.5 KRT161 150 8.2 1w HAS1 22.7 939.7 1378.5 11:11 SPRR2G 1.8 70 11.3 1 9.6 817.1 19.2§\\\\\\ PCDH1O 1 38.4 7.4 .11.11 -0.9 89 90.9&\\\\ PCDH10 -1.4 9.9 11.2 9 9 Table 2 PCDHA7 PCDHBS AM|G02 CATNAL1 479_9 \fl COL5A2 \\\\\ Table 2 H868T1 395.4 1824.5 349 ITGA2 5.6 49.3 13.1 ITGAS 157.4 332.9 164 ITGA6 1 9 4.1 ITGAD 1.5 3 —0. 2.1 18.2 —5.4§§\\\\\\ ITGAE 1 10 8.4 10.0 ITGAV 59.2 172.4 ITGB2 2.7 53.1 8 19.7 ITGB6 180 620.7 ITGB6 1253.2 3474.8 ITGB6 513.8 1370.7 ITGP 1 10.6 KRT14 254.8 1063 KRT1-5 1 18.6 -2.1 18.6 KRT16 1 150 1.2 148 16 K8723 679.4 4234.8 KRT36 6.5 60.5 K8717 7.7 103.2 65.5 13.4 KRT33B -1.8 7.9 0.8 7.9 K8735 -4.4 12.1 85.9 12.1 K8782 -0.6 18.2 3.6 18.2 K8784 0.8 8.1 20.4 8.1 K8786 -1.7 12.9 4.6 12.9 6-5 0.3 14.1 34.6 14.1 KRTAP3-2 -2.7 7.9 -5.9 7.9 KRTAP9-1 —1 7.7 49 7.7 KRTDAP 19.2 157.7 258.3 8.2 10x14 2.7 21.6 7.6 SPRRZD 6.1 1052.3 -0.1 1.1 3215.9 14.1 SPRRZE 1 245.5 -8.1 —1.9 772.1 —4.5 SPRRZF 14.4 137.8 9.1 9.6 5.9 2404.5 45.6 SPRRZG 1.8 70 11.3 a 9.6 817.1 19.2& CDCP1 5.8 43.7 21875 AMICAl 22.2 372.2 455 16.8 CDH2 10.2 74.1 10.8 7.3 10x14 43 469.9 373.6 10.9 NRXN2 6.5 78.9 153 12.1 Emfi‘fiifilf 388838333 8383838288838 VCAM1 5.4 68.1 34.9 0.8 45 -6.6 VCAM1 637.4 4462.9 3422.1 0.9 14.9 9.4 ICAM1 329.6 7607.4 4220.4 256.4 2069.1 705.5 SELP 36.5 225.9 1068. 28 756.9 . 2978.1§ SELL 4.3 10 6.6 8.8 84.1 26.8 9.6 CEACAMl 12 137.2 72.8 11.4 CEACAMl 42.4 303.9 59.4 7.2 CEACAM2 50.4 408.1 22 8.1 REL 1 132.3 NFKBIZ 147.6 6159.8 NFKBID 40.9 1493.2 IKBKE 90.1 569 NFIB 3.5 9 NFKB1 20.5 151.3 7.4 69.9 144§\\\\\\ NFKB1 561.3 2247 840.7; NFKB2 1 6.8 -0.5§ NFKBIA 630 11386.8 6795.9 18.1 18.1 301.2 226.9 NFKBIA 27.7 338.8 182.1 12.2 NFKBIB 19.8 200.7 46.8 10.1 17.9 264.1 221.6 NFKBID 40.9 1493.2 362.5 2 27.8 399 248.8 NFKBIE 8.1 180.2 29.6 22.2 60.2 536 169.6 NFKBIE 60.2 731.7 136 12.2 164.2 3145.7 2250.7 NFKBIZ 147.6 6159.8 2878.9; REL 1 132.3 263 RELA 5 1948.7 4768.8 2897 RELB 106.2 1265.6 336 HSPA1A 64.7 744.8 HSPA1A 35.2 239.8 HSPA1A 1469.1 5421.2 g HSPA1 B 22.6 227.3 22.7 10.1 HSPA1 B 135 1184.7 193.7 8.8 HSP90AA1 6.6 49.3 77.1 7.5 HSPA14 -11.8 8 -3.9 8.0 HSPBB -0.4 19.8 44.3 19.8 c0x4|2 22.2 236.9 358.2 10.7 LTB4R1 28.9 222 363.3 7.7 NKIRASl 14.9 135.5 189.4 9.1 RIPK2 79.7 819.8 ::::::::::::::lQ-:3 :mmmgw: KCNE2 | 1.8 68.8 MCOLN2 12.8 42.3 7.2 108.2 7.9 0ch 33.1 66.2 10.2 116.5 193.5k CL|C4 121.4 459 CLIC6 33.9 494.6 73.1..-.

CACNAlF 1 10 4.1 CACNG3 -8.9 9.4 -0.8 .

CACNGS -1.6 16.1 47.9 16.1 CACNG6 1 13 7.9 13.0 CLCA3 5.3 46.1 -4.1 8.7 CLCN3 1.3 10.7 -2.6 8.2 CLCNKA -0.8 7.3 5.3 7.3 CLIC6 33.9 494.6 73.1 14.6 Table 2 KCNAlO KCNA7 KCNABl KCNC2 KCNDZ KCND3 KCNElL KCNH4 KCNJl KCNK13 KCNK15 KCNK9 KCNQ2 KCNQ2 KCNQ5 KCNS3 SCN2A1 SCN8A SCNMl SCNMl TPCNl MCOLN2 Table 2 RANBP3L RANGAPl CDGAP IRGC RAB20 RAB32 RHOF RABl RABlB RAB3B RAB3|P2—PEND RABSB RAB7 RAPlA RASALl RASGEFlA RASGRPl RASSFlO RASSF4 RASSF6 RASSF9 ARHGAPlS ARHGAP25 ARHGAPS ARHGEFl ARHGEF7 We “L. >¢Ax 3 E“? $§KE€§E§$“ ' SERPINASF . . . \\\\-~ SERPINASG . . .

SERPINA3H . . . i \v“ SERPINASN .

B1A .

SERPINB2 SERPINA12 SERPINAlC SERPINA3G SERPINA3M SERPINB3B SERPINEZ SERPINFZ CST6 STFAl Table 2 SLClOAS . . . 27.5 SLC10A6 SLC10A6 \ SLC1 1A2 .

SLC1 1A2 SLC12A1 14.1 SLC12A2 . . . 7.4 SLC13A3 . 7.8 SLC14A2 . 29.0 SLC15A3 \N.

SLC16A3 SLC1 6A5 SLC1 6A9 E ' \\\\““at; “A k a V‘} SLC17A3 SLC17A6 SLC1 A4 SLC25A25 SLC2A6 SLC22A6 SLC22A9 SLC24A5 SLC25A2 SLC25A34 SLC25A4 SLC25A4O SLC25A4O SLC26A4 SLC26A7 SLC29A4 SLCZAZ SLC2A6 SLC3OA3 SLC3OA4 SLC34A2 SLC35F4 SLC36A3 SLC38A1 SLC38A2 SLC39A8 SLC39A8 SLC45A3 SLC39A4 SLC39A5 SLC3A2 SLC45A2 Table 2 SLC4A1 SLC4A4 SLC5A1 SLC5A10 SLC5A2 SLC6A12 SLC6A15 SLC6A16 SLC6A2 SLC6A4 SLC7A11 SLC7A2 SLC7A9 SLC8A2 SLC9A6 SLC01A5 SLCO4A1 SLCO6B1 OLFRl OLFR100 OLFR1000 OLFR101 OLFR1015 OLFR1024 OLFR1040 OLFR1042 OLFR1048 OLFR1056 OLFR1061 OLFR1065 Table 2 OLFR1085 OLFR1102 OLFR1109 OLFR1112 OLFR1129 OLFR113 OLFR113O OLFR1133 OLFR1138 OLFR1148 OLFR115 OLFR1170 OLFR1176 OLFR1178 OLFR1181 OLFR1186 OLFR1198 OLFR120 OLFR1223 OLFR1232 OLFR1249 OLFR1250 OLFR1260 OLFR1288 OLFR1309 OLFR1320 OLFR1323 OLFR1331 OLFR1333 OLFR1337 OLFR1344 OLFR1347 OLFR1348 OLFR1349 OLFR1361 OLFR1384 OLFR139O OLFR1406 OLFR1412 OLFR1424 OLFR1437 OLFR1443 OLFR1444 OLFR1453 OLFR1474 Table 2 OLFR1475 OLFR148 OLFR1489 OLFR1508 OLFR1513 OLFR159 OLFR165 OLFR166 OLFR167 OLFR168 OLFR168 OLFR171 OLFR176 OLFR192 OLFR26 OLFR262 OLFR27O OLFR272 OLFR293 OLFR31 OLFR312 OLFR351 OLFR362 OLFR376 OLFR380 OLFR415 OLFR429 OLFR432 OLFR434 OLFR458 OLFR464 OLFR467 OLFR470 OLFR478 OLFR48 OLFR486 OLFR49O OLFR5 OLFR510 OLFR516 OLFR517 OLFR524 OLFR525 OLFR530 OLFR535 OLFR536 Table 2 OLFR538 OLFR558 OLFR56 OLFR566 OLFR57 OLFR578 OLFR597 OLFR606 OLFR616 OLFR618 OLFR619 OLFR62 OLFR630 OLFR638 OLFR639 OLFR64 OLFR654 OLFR658 OLFR659 OLFR665 OLFR677 OLFR681 OLFR691 OLFR692 OLFR698 OLFR702 OLFR710 OLFR716 OLFR722 OLFR725 OLFR731 OLFR744 OLFR748 OLFR76 OLFR761 OLFR781 OLFR786 OLFR796 OLFR812 OLFR816 OLFR821 OLFR824 OLFR826 OLFR828 OLFR829 OLFR851 Table 2 OLFR855 OLFR868 OLFR869 OLFR871 OLFR872 OLFR881 OLFR906 OLFR910 OLFR912 OLFR917 OLFR951 OLFR974 OLFR976 OLFR98O OLFR983 OLFR987 OLFR99 OLFR995 WM? 31:“? ’1 V1RA2 VlRBQ V1RC10 V1RC8 V1RD12 V1RD2 V1RD20 V1RD3 V1RE12 V1RE13 V1RF3 V1RG3 V1RH13 V1RH21 v1m1 V1RJ3 VlRLl Sismifix..- u CHSTll ASPN Table 2 PCDHlO PCDHlO PCDHAll PCDHA7 PCDHA7 PCDHB6 PCDHGAlO PCDHGB6 PCDHGB7 PCDHGB8 Table 2 PRL2C2 -3.4 20.1 6.9 20.1 PRL2C3 -3.5 8.2 21.6 8.2 PRL3D3 1 10.7 40.5 10.7 PRL4A1 -5.4 7.6 —2.5 7.6 PRL7A2 -6.8 7.6 —5.3 7.6 Pmiagiifi § § ‘ PRLR 22.5 173.6 257.9 7.7 "NNN {Nd TNNWNNN 8.3 TNF 1 854.3 94.3 0.5 21.4 4.2 TNF 3 1170.4 143.3 390.1 -4.2 9.3 17.7 T\FA|P2 685 9076.5 1738.9 13.3 T\FA|P2 951.4 10471.8 2463.2 11.0 T\FA|P2 1876.9 15829.8 5120 8.4 T\FA|P3 42.3 2753.3 1202.9 0.5 21.4 4.2 TNFSFlO -4.6 40.8 111.2 40.8 T\FRSF1OB 20 104.7 28.5 5.2 -4.2 9.3 17.7 T\FRSF1OB 12.1 41.2 21.9 3.4 -4.1 21.7 —5.7k T\FRSF12A 307.7 1962.6 1503 6.4 T\FRSF1B 19.7 62.1 36.3 3.2 T\FSF11 4.5 66.1 35.1 14.7 T\FSF12—TNF 2.6 20.4 10.3 7.8 TNFSF13B -0.9 7.2 1.2 7.2 4 4.3 29.5 74 29.5 TNKS 3 84.9 116.2:::::::::::::::28.:3 TNFSF9 TN|P1 9.4 40.4 TN|P1 149.9 601.5 TRAF1 12.6 52.6 TRAFG 37.9 96.8 BATS 104 898 31386 \NQNN § 3“ 888.3 NM“ NR4A2 8.1 97.3 97.2 12.0 NR4A3 1 30.7 25.5 7 NR4A3 1 28.9 23.8 28.9 Table 2 QfififlgfifiQS VAVl umpmm ERAF HA may: :wfhd§wmshw Al987692 AIM1 L AKAP1 AKAP12 AKAP2 AKAP2 AKAP2 AKAP4 AKAP8 AKR1BB AMD2 ANGPTL4 ANKRD1 ANKRD1 Table 2 ARG1 ATP10D AXUD1 B230378H13R BACH1 BCAR3 BDH1 C330006D17R 6P03R C730046CO1R CCDC155 CCDC21 CCDC49 CCDCBSB CCDC89 CCDCQQ CCT7 CDCSL CDCA4 CDCA5 CLN5 000108 000108 CTPS CYR61 DGAT2 DONSON DONSON ERRH1 Table 2 GTLFSA 40.6 HDC 137.9 HP 508.4 HP 334.8 HP 938.3 IDS 21.8 IHH 23.2 |NSl 11.8 |NS|G1 217.4 |NS|G1 221.6 INSR 8.7 14.1 48.6 13.6 57.5 16.3 49.4 KLH L25 383.8 LDLR 136.3 LPK 50.6 IVARCKSL1 162.6 MARCO 11.9 IVA—2A 107.7 IVA"2A 412.6 IVA—2A 173.3 IVA"2A 5883.3 IVA"N4 6.8 |VCM10 9.3 IVCM1O 42.9 IVCOLN2 42.3 MFSD2 1933.3 |V|D1 48.5 |VOBKL1A 2.9 15.9 |VOBKL2A 79 209.2 lVOGAT2 22.2 72.5 lVOGAT2 6.7 16 1 3 21.8 IVRGPRAZ 5.5 20.2 11776.7 23326.9 45.3 178.4 MTMR14 59.2 173.6 MTMR14 50.8 118.4 MVD 423.3 1508.7 MYBBP1A 97.9 191.9 MYD116 256.8 1849 MYOM2 4.2 27.9 Table 2 NFXU NFYA NGFB NGFB NHLRCS NLE1 NOC3L NOL1 NRG1 NRP3 NSUN5 NUAK2 NUPR1 OASL1 OASL1 PCDH1O PDE4A PDE4B PDE4B PDE4B PDE6G PDGFB PDGFB PEU1 PEUB PHLDA1 HK3C2A PLCXD3 PLEK PLEKHG2 PLEKHG2 PMAP1 PMAP1 PMP22 POF1B PPAN PRDM2 PRDM2 PRR7 PRSSZ2 PRSSZB PRSSZ7 PTGES PTGES PTGFRN PTPN12 PTPN12 PTPN12 PTPN12 PTPN2 RAMP3 RCAN1 RDH10 RCAN1 RDH10 RETNLG RRP1B RUNX1 SBNO2 SGK1 SHSBP2 SNAB SNFlLK SPSB1 ST3GAL1 STK35 SYNGRZ TAC1 TAL1 TAX1BP3 TBC1D1OA TBC1D1OA TGF1 TGM1 THBS1 'HMP1 TREX1 TR|M21 TR|M27 TRPV4 TRPV4 TSSK6 TTCSQB UPP1 VPS3YB VVDR4 VVDR43 VVDR46 VVDRTO VVDR82 VVDR92 VVNT1OB Table 2 VVNT7B 3534 VVSB1 12897 YBX3 175592 ZFP295 30.4 ZFP36 66829 ZFP57 6&7 ZFP607 1145 ZSMHM4 6567 ARMCl CHD7 CHKA EEF1A2 FABPS FBN1 FFARZ Table 2 SLAM F8 SPINK8 T| MELESS Table 2 ATG4D ATP50 BACE2 BNPl CALCA CH25H CRYBG3 DDAHl EPSTIl GNGlS LOC100047934 047963 LOC100048556 LOC638301 NEK6 OSMR PCNP SCL0002368.1 STFAl STFAZ APOLD1 30037703 CH25H Table 2 -7.6 \1 671.7 .§\\ th Mr. \\\\V§$:&$&N\\\\\\‘ PSORS102 A630077B13R A230065H1 6R 1190003J15R| 1500041 J02R| 2310014HO1R 2310016C08R 2310016008R 2210008FO6RI AI607873 A|987692 AIM-1 L 231 00141.101 RIK 2310016008R|K 2310016C08R|K 2310025JO1R|K 2310051F22RIK 2410025L10R1K 2810402K13R|K 2E14RIK 5033413D16R|K 5530400801 RIK 583045701 OHIK 9930023K05RIK 9930122J16R|K A130051J06RIK A130082|\/|07RIK 5H16R|K L0C10004623 Table 2 LOC1 0004726 LOC1 0004733 LOC1 0004777 LOC1 0004793: LOC10004855 LOC1 0004855 LOC212399 LOC381 140 LOC638301 D17H6856E-3 D17H6856E-5 D330008|21R|1 D7BWG061 1 E D930038018R D930039D09R

Claims (23)

The claims defining the invention are as follows:

1. Use of a Toll-Like Receptor (TLR) agonist for the manufacture of a medicament for the treatment of cancer in a , n the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising an amino acid sequence of at least 95% identity with SEQ ID NO:

2. The use of claim 1, wherein the cancer is a metastatic.

3. The use of claim 1 or 2, wherein the cancer does not express TLR.

4. The use of any one of the preceding claims, n the tissue is ed from the group consisting of liver, lung, bladder, and intestinal.

5. The use of any one of claims 1 to 4, wherein the cancer is ed from the group consisting of melanoma, colon, breast, prostate, and a hematological malignancy.

6. The use of any one of claims 1 to 5, wherein the cancer is a tumor.

7. The use of claim 5, wherein the hematological malignancy is lymphoma.

8. The use of any one of claims 1 to 7, wherein the medicament is used as a monotherapy.

9. The use of any one of claims 1 to 8, wherein the mammal is not receiving a combination cancer therapy.

10. The use of claim 9, wherein the mammal is not receiving chemotherapy or radiation therapy.

11. The use of any one of claims 1 to 10, wherein the mammal has sufficient innate immunity.

12. The use of claim 11, wherein the sufficient immunity level is equivalent to the level required for eligibility for a first or subsequent round of chemotherapy.

13. The use of claim 11 or 12, wherein the mammal has a white blood cell count that is within the range of clinically normal.

14. Use of a Toll-Like Receptor (TLR) agonist for the cture of a ment for the treatment of cancer in a mammal, wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8.

15. The use of claim 15, wherein the cancer does not express TLR.

16. The use of claim 14 or 15, wherein the tissue is selected from the group consisting of liver, lung, r, and intestinal.

17. The use of any one of claims 14-16, n the cancer is ed from the group consisting of melanoma, colon, breast, prostate, and a hematological malignancy.

18. The use of claim 4, wherein the tissue is liver.

19. The use of claim 18, wherein the cancer is metastatic colon cancer.

20. The use of claim 18, wherein the cancer is metastatic lymphoma.

21. The use of claim 16, n the tissue is liver.

22. The use of claim 21, wherein the cancer is metastatic colon cancer.

23. The use of claim 21, wherein the cancer is metastatic lymphoma.